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despite major improvements in treatment and prevention over the last decades, 
cardiovascular disease is still one of the leading causes of morbidity and mortality 
worldwide.1, 2 in europe, cardiovascular disease is responsible for approximately 
four million deaths each year. low-dose aspirin is a cornerstone in the prevention 
of cardiovascular disease, because it reduces the risk of recurrent cardiovascular 
events with about a quarter.3 Historically, the natural form of aspirin (salicin) was 
extracted from willow tree bark (salix) which was already used in ancient egypt 
and Greece to treat pain and fever.4 Major drawbacks of this ancient drug were 
its side effects, especially irritation of the stomach. in 1897, a chemist named Felix 
Hoffman modified the compound into acetylsalicylic acid to reduce its side effects. 
The bayer company registered the substance under the name “Aspirin®” as a pain 
killer in 1899.5 A bleeding tendency in patients using aspirin was already reported 
in 19456, but the effect of aspirin on blood platelets was not known until 1968.7 
even before this mechanistic discovery, a general practitioner named lawrence 
craven was one of the first to systematically investigate the possible role of aspirin 
to prevent myocardial infarctions in 1950 (Figure 1).8 He recommended all his male 
patients between the age of 40 and 65 years to take aspirin, and observed no 
myocardial infarctions. Followed by large randomized placebo-controlled trials in 
the 80s, the role of low-dose aspirin in the prevention of cardiovascular disease was 
established.9 in the current era new benefits of aspirin continue to be discovered, 
BA C D
Figure 1 – (A) Aspirin, in the form of salicin extracted from willow bark or -leaves, was already 
used by the ancient egyptians, as recorded in the ebers papyrus roll. The Greek medical doc-
tors (e.g. Hippocrates) later adopted this treatment. (B) in 1897, a bayer company chemist Felix 
Hoffman, purified acetylsalicylic acid. (c) Aspirin tablets in an early (pre-1921) bayer bottle. 
(D) The general practitioner lawrence craven was one of the first to systematically describe 
the protective effect of aspirin on myocardial infarction. With permission from respectively 
the leipzig university library, bayer Healthcare, eric e. Johnson and the Minnesota university 
library.
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for example in the prevention of cancer.10 in this thesis, we investigate a new strat-
egy to improve the effectiveness of aspirin: the reduction of blood pressure and 
morning platelet reactivity by taking aspirin at bedtime instead of on awakening.
bedTiMe Aspirin And blood pressure
High blood pressure (hypertension) is an important risk factor for cardiovascular 
disease. it is believed to cause 22% of all heart attacks in western europe.11 even 
small reductions of blood pressure (3 to 5 mmHg) decrease the risk of myocardial 
infarction and stroke in population-based studies.12, 13 Although there are many 
different antihypertensive agents, the blood pressure goal of ≤140/90 mmHg is 
reached by only half of all hypertensive patients.14 Thus, simple and effective 
interventions to improve blood pressure control could have a large impact on the 
incidence of cardiovascular disease.
Aspirin, a non-steroidal anti-inflammatory drug (nsAid), was originally thought 
to increase blood pressure, because it inhibits blood pressure lowering prosta-
glandin synthesis. However, in contrast to other nsAids, aspirin was shown not 
to increase blood pressure in a meta-analysis.15 in recent studies aspirin was even 
associated with considerable reductions of blood pressure (5 to 7 mmHg), but only 
when taken at bedtime instead of on awakening.16-18 An insight into the mecha-
nism behind this remarkable time-dependent effect of aspirin on blood pressure 
was given by the Aspirin in reduction of Tension i (AspireTension i) study.19 in 
this study, aspirin intake at bedtime compared with intake on awakening reduced 
parameters known to influence blood pressure, such as plasma renin activity and 
24 hour cortisol, dopamine and norephinephrine excretions.19 However, these stud-
ies were conducted in healthy participants, patients with untreated hypertension 
or pregnant women, all without a clear clinical indication for aspirin use.20 use 
of low-dose aspirin is only indicated when benefits outweigh the harms (bleed-
ing). until now, this is only the case for patients who are at high risk for or have 
established cardiovascular disease.9, 20, 21 yet, the potential blood pressure lowering 
effect of bedtime aspirin was never assessed in patients with established cardiovas-
cular disease, who may also use concomitant antihypertensive drugs and who have 
more advanced atherosclerosis than patients in previous studies. in the Aspirin 
in reduction of Tension ii (AspireTension ii) study, described in chapter 3, we 
assessed whether aspirin intake at bedtime compared with intake on awakening 
also reduces blood pressure of patients already using aspirin for prevention of 
cardiovascular disease.
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bedTiMe Aspirin And MorninG plATeleT reAcTiviTy
platelets are small anucleated cells, of which large numbers (150-450 x 109/l) are 
present in the human blood.22 platelets have a lifespan of 7-10 days and new 
platelets are constantly produced by bone marrow megakaryocytes. To maintain a 
stable physiological concentration, new platelets are released at a rate of 10% per 
day. in normal conditions platelets circulate in the bloodstream in a resting state. 
However, where blood vessels are damaged, platelets are exposed to stimuli and 
get activated, change their shape and aggregate to form a hemostatic plug.23, 24 
This is beneficial where hemostasis is needed, but harmful when a plug forms on 
a ruptured or eroded atherosclerotic plaque and causes myocardial infarction or 
stroke.
Already in the 1980s, a circadian rhythm was observed in the frequency of acute 
cardiovascular disease, with the highest incidence during the morning hours (6 
to 12 AM).25 in a meta-analysis the excess risk of acute cardiovascular events dur-
ing morning hours was estimated to be around 40%.26 Also in patients treated 
with cardiovascular drugs such as platelet inhibitors and beta-blockers, recurrent 
events occur in a circadian pattern.27 After the discovery of the morning peak in 
cardiovascular events it was shown that platelet reactivity also follows a circadian 
rhythm, with a peak of platelet reactivity during the morning (6-12 AM).28-32 Given 
the important role of platelets in the development of acute cardiovascular events, 
it is reasonable to assume that the morning peak of platelet reactivity contributes 
to the morning peak of acute cardiovascular events.33 if true, reduction of morn-
ing platelet reactivity might prevent arterial thrombosis during morning hours 
and thereby prevent a proportion of morning cardiovascular events. This may be 
achieved by intake of aspirin at bedtime instead of on awakening.
After intake, aspirin is rapidly absorbed by the stomach and small intestine, 
reaching its maximal concentration in blood already after 20 minutes. Thereafter, 
aspirin is rapidly de-acetylated and cleared from the circulation.34 Aspirin inhibits 
platelet reactivity by inactivating the platelet cyclo-oxygenase-1 enzyme, thereby 
preventing the production of thromboxane A2, a potent amplifier of platelet ag-
gregation. because platelets lack the dnA to renew the enzyme, cyclo-oxygenase-1 
is inhibited by aspirin for the whole lifespan of a platelet (7-10 days). still, aspirin 
has to be taken each day, because new platelets are released at a rate of 10% per 
day.35 These newly released platelets are uninhibited by aspirin and are capable to 
produce thromboxane A2.
35 it has been suggested that the presence of 10% unin-
hibited platelets is enough to abolish the effect of aspirin on platelet reactivity.7, 36 
importantly, previous studies showed that 95% of all platelets have to be inhibited 
by aspirin to achieve an effective reduction of platelet reactivity.37
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With a daily platelet turnover of 10%, this implies that only 90% of all platelets 
are inhibited by aspirin at the end of its dosing interval (24 hours after intake), 
whereas 95% inhibition is needed to achieve effective inhibition of platelet 
reactivity.37 This is also supported by a recent study, which showed that platelet 
aggregation was insufficiently inhibited 24 hours after morning aspirin intake in 
25% of the patients with established cardiovascular disease.38 The majority of pa-
tients take their aspirin on awakening, which in most cases is after the start of the 
morning peak of platelet reactivity at 6 AM. consequently, after morning aspirin 
intake, 10% of platelets are uninhibited just before the next morning intake 24 
hours later. so, with aspirin intake on awakening, 10% uninhibited platelets are 
present during the morning hours, when the risk of cardiovascular events is the 
highest (Figure 2). because it is desirable to achieve optimal inhibition of platelet 
reactivity during the high risk morning hours, it might be beneficial to take aspirin 
at bedtime instead of on awakening. by taking aspirin at bedtime, the proportion 
of uninhibited platelets during morning hours would theoretically be reduced to 
5%, and thereby inhibition of platelet reactivity is more effectively achieved dur-
ing morning hours (Figure 2).This was already suggested by previous authors39-41, 
but for the first time we evaluate this in clinical trials, described in chapter 3 and 4.










































Figure 2 – Theoretical representation of the effect of aspirin intake on awakening (9:00h) or at 
bedtime (23:00h) on the proportion of uninhibited platelets during 24 hours. The grey shaded 
area represents the timing of the morning peak of cardiovascular events and platelet reactivity. 
short after aspirin intake, all platelets are inhibited (0% uninhibited). subsequently, new plate-
lets are released at a rate of 10% per day. due to aspirins short half-life, these newly released 
platelets are uninhibited. This implies that 10% uninhibited platelets are present 24 hours after 
aspirin intake, which is situated during the high risk morning hours when aspirin is taken on 
awakening (panel A). The proportion of uninhibited platelets during the morning hours is 
theoretically reduced to 5% by taking aspirin at bedtime (panel B). This might be beneficial, 
because it is known that 95% platelet inhibition is required to achieve a clinically effective 
reduction of platelet reactivity by aspirin.
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AiMs And ouTline oF THis THesis
The main aim of this thesis is to assess the effect aspirin intake on awakening com-
pared with intake at bedtime on blood pressure and the morning peak of platelet 
reactivity. both outcomes are particularly suitable to study with a cross-over study, 
which carries specific methodological advantages. chapter 2 gives an introduction 
to cross-over studies, which helps to understand the design and methodology of 
the studies in subsequent chapters. chapter 3 and 4 describe the results of two 
clinical trials, which were carried out to investigate the time-dependent effect of 
aspirin on blood pressure and platelet reactivity. To examine the effect of platelet 
reactivity on the risk of secondary cardiovascular events, we carried out a cohort 
study in men who survived a first myocardial infarction, which is described in 
chapter 5. Following international guidelines, patients with cardiovascular disease 
take several medications on a daily basis, of which beta-blockers are one of the 
most frequently prescribed. However, there is still debate about the effect of beta-
blockers on platelet reactivity. by performing a systematic review and meta-analysis 
in chapter 6 we synthesize all available evidence and estimate the magnitude of 
beta-blockers’ effect on platelet reactivity. in chapter 7 we summarize and discuss 
the results of the studies presented in this thesis.
16 chapter 1
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sAMenvATTinG
•	 Voor	 een	 gerandomiseerde	 parallelle-groep	 trial	 zijn	 vaak	 grote	 groepen	
patiënten nodig, wat veel tijd en kosten met zich meebrengt.
•	 In	sommige	gevallen	kan	een	gerandomiseerde	cross-over	trial	een	voordeliger	
en efficiënter alternatief zijn.
•	 Cross-over	 studies	 kunnen	 gebruikt	 worden	 bij	 chronische	 aandoeningen,	
waarbij het effect van de behandeling tijdelijk is.
•	 Elke	deelnemer	krijgt	in	opeenvolgende	perioden	alle	behandelingen,	waarbij	




voorkomen kunnen worden door een wash-out periode van voldoende duur in 





effecten van behandelingen kunnen op verschillende manieren gemeten worden. 
in de praktijk is de meest gebruikte studie opzet een gerandomiseerde parallelle-
groep trial. deze opzet heeft echter als belangrijk nadeel dat er vaak grote groe-
pen patiënten nodig zijn, wat veel tijd en kosten met zich meebrengt. in sommige 
gevallen is een cross-over studie een efficiënter en goedkoper alternatief. in dit 
overzichtsartikel bespreken we aan de hand van voorbeelden uit de praktijk wat 
een cross-over studie is, wanneer deze opzet mogelijk is en wat de voor- en na-
delen zijn. Ten slotte bespreken we beknopt hoe cross-over studies geanalyseerd 
worden. voor een compleet overzicht over cross-over studies verwijzen wij naar 
het boek van senn.1
WAT is een cross-over sTudie?
in een cross-over studie krijgt elk individu in opeenvolgende perioden alle behan-
delingen die onderzocht worden, waarbij de uitkomsten gemeten worden aan 












24-uursbloeddrukmeting en meting van trombocytenactiviteit
periode 1 periode 2
 
Figuur 1 – de Aspiretension-ii-studie (Aspiretension staat voor ‘Asprin in reduction of tension’) 
is een lopende studie naar het effect van inname van acetysalicylzuur 100 mg ’s ochtends of ’s 
avonds op de bloeddruk en trombocytenfunctie over de dag (www.clinicaltrials.gov; zoek op 
ncT01379079). de hypothese is dat inname van acetylsalicylzuur ’s avonds de bloeddruk en de 
ochtendpiek van trombocytenreactiviteit verlaagt. in totaal worden 252 patiënten die acetyl-
salicylzuur gebruiken ter secundaire preventie van hart- en vaatziekten gerandomiseerd voor 
inname ’s ochtends of ’s avonds voor een periode van 3 maanden (periode 1). na 3 maanden 
vindt een cross-over plaats van het tijdstip van inname, waarna deelnemers nog 3 maanden ’s 
ochtends of ’s avonds acetylsalicylzuur gebruiken (periode 2). na 3 en 6 maanden worden een 
24-uursbloeddrukmeting en een meting van de trombocytenreactiviteit in de ochtend gedaan.
24 chapter 2
binnen een individu in plaats van tussen groepen individuen. de meest eenvoudige 
opzet van een cross-over studie is een studie met twee interventies verdeeld over 
twee perioden. dit wordt ook wel een 2x2-, ofwel Ab/bA design genoemd. een 
voorbeeld hiervan is de Aspiretension ii studie, waarin de invloed van aspirine 
inname ’s ochtends versus ’s avonds op de bloeddruk en trombocytenreactiviteit 
wordt onderzocht (Figuur 1). net als bij een parallelle-groep studie wordt aan het 
begin van een cross-over studie gerandomiseerd. Het verschil is dat niet wordt 
gerandomiseerd voor de behandelingen maar voor de vólgorde van de behande-
lingen. Het nut hiervan wordt verderop in dit artikel besproken. idealiter worden 
onderzoekers en deelnemers in een cross-over studie geblindeerd voor de volgorde 
van behandeling en wordt gebruik gemaakt van een placebo. in een cross-over stu-
die kunnen ook meer dan twee behandelingen vergeleken worden. een voorbeeld 
hiervan is de dAsH-sodium studie (Tabel 1), waarin de invloed van twee soorten 
dieet en drie verschillende zoutgehalten op de bloeddruk werd onderzocht.2, 3
GroepsGrooTTe
Het grootste voordeel van een cross-over studie is dat er in totaal minder patiën-
ten nodig zijn. de rede hiervoor is dat in een cross-over studie de variatie tussen 
individuen geen rol meer speelt. bij de berekening van de groepsgrootte hoeft 
dan alleen rekening gehouden te worden met de variatie binnen individuen, die 
meestal kleiner is dan de variatie tussen individuen. de variatie binnen een indi-
vidu kan worden uitgedrukt als de samenhang (correlatie) tussen de herhaalde 
metingen binnen een individu. Hoe hoger deze samenhang, hoe lager de variatie. 
Als er géén samenhang is, is voor een cross-over trial maar de helft van het aantal 
patiënten nodig vergeleken met een parallelle-groep studie. dit komt doordat de 
vergelijking plaatsvindt binnen één groep in plaats van tussen twee groepen. in 
Tabel 1 voorbeeld van een cross-overstudie met meerdere behandeling
DAsH-sodium-studie
de ‘dietary approaches to stop hypertension (dAsH)-sodium’-trial is tot nu toe de grootste en meest 
geciteerde cross-overstudie.2 Het bijzondere van deze studie is dat het een parallelle opzet combi-
neert met een cross-overopzet. de deelnemers (n = 412) werden eerst gerandomiseerd voor het vol-
gen van een satndaard Amerikaans dieet of het dAsH-dieet, rijk aan groenten en fruit met weinig 
vet, suikers en verzadigde vetten. vervolgens werd er binnen deze 2 groepen gerandomiseerd voor 
de volgorde van 3 periodes van 1 maand met een laag, gemiddeld of hoog zoutgehalte. na elke 
periode van 1 maand vond cross-over plaats naar een ander zoutgehalte. elke deelnemer gebruikte 
dus 1 van de 2 diëten voor 3 maanden in een opzet met parallelle groepen en elk zoutgehalte voor 
1 maand in een cross-overopzet. Aan het eind van elke periode werd de bloeddruk gemeten. bij 
de deelnemers met een standaard dieet zorgde het lage zoutgehalte in vergelijking met een hoog 
zoutgehalte voor een gemiddelde systolische bloeddrukdaling van 6,7 mmHg.
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de praktijk is er echter altijd samenhang tussen herhaalde metingen binnen een 
individu. dit verlaagt het aantal benodigde patiënten voor een cross-over studie 
verder. Als voor een parallelle-groep studie (bij gelijke power en een gelijk signifi-
cantieniveau) Nparallel patiënten nodig zijn, dan is het aantal patiënten dat nodig is 
voor een cross-over studie (Ncross-over) eenvoudig te berekenen met de formule:
Ncross-over = (1-r) Nparallel /2
waarbij r de samenhang (correlatie) is tussen de herhaalde metingen binnen een 
individu.4 de groepsgrootte voor een parallelle-groep studie (Nparallel ) kan worden 
berekend volgens de gebruikelijke methoden.5 Figuur 2 illustreert, gebaseerd 
op bovenstaande formule, dat de benodigde groepsgrootte voor een cross-over 
studie afhankelijk is van de samenhang (correlatie, r) tussen de herhaalde met-
ingen binnen individuen. in de praktijk komt vaak een correlatie van rond de 
0.5 voor, waardoor voor cross-over studies meestal maar een kwart van de totale 
groepsgrootte van een parallelle-groep studie nodig is. de precieze correlatie kan 
worden ontleend aan eerdere studies met herhaalde metingen of worden berek-





































Figuur 2 – benodigde groepsgrootte voor een cross-overstudie om met dezelfde precisie het-
zelfde effect aan te kunnen tonen als een studie met parallelle groepen met 100 deelnemers. 
Als er geen samenhang is (r = 0) tussen de herhaalde metingen, is voor een cross-overstudie de 
helft van het aantal patiënten nodig. in de praktijk is de correlatie meestal rond 0,5, waardoor 
voor de meeste cross-overstudies maar een kwart van de totale groepsgrootte voor studie met 
parallelle groepen nodig is.
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nAdelen vAn cross-over sTudies
carry-over
Als behandelingen vergeleken worden in opeenvolgende perioden kan het voor-
komen dat de behandeling van periode 1 nog doorwerkt in periode 2. Het effect 
van	de	behandeling	in	periode	2	kan	dan	beïnvloed	worden	door	het	doorwerken	
van de behandeling in periode 1. dit wordt het carry-over effect genoemd. een 
manier om een carry-over effect te voorkomen is het inbouwen van een uitwas-
periode (wash-out) tussen de periodes waarin geen behandeling wordt gegeven. 
Men neemt dan aan dat de metingen in de volgende periode niet meer worden 
beïnvloed	door	de	behandeling	in	de	voorafgaande	periode.	Een	wash-out	peri-
ode moet lang genoeg zijn om zoveel mogelijk te garanderen dat de interventie 
uitgewerkt is voordat de metingen in de volgende periode gedaan worden. in 
de praktijk is het van belang rekening te houden met de werkingsduur van de 
interventie. Aangeraden wordt om een periode van minimaal 4x de werkingsduur 
van het middel te nemen.1
soms is een wash-out praktisch niet mogelijk of ethisch niet verantwoord. de 
interventie periodes kunnen dan langer gemaakt worden, zodat de uitwas van de 
behandeling in de voorafgaande periode zoveel mogelijk gegarandeerd wordt. in 
de Aspiretension ii studie (Figuur 1) is het medisch en ethisch niet verantwoord om 
patiënten die aspirine gebruiken ter secundaire preventie van hart- en vaatziekten 
in een wash-out periode geen aspirine te laten gebruiken. daarom kozen de on-
derzoekers voor een interventieperiode van 3 maanden, waardoor het effect van 
aspirine (werkingsduur 7-10 dagen) in periode 1 uitgewerkt is voordat de metingen 
aan het eind van periode 2 plaatsvinden. ook in de dAsH-sodium trial (Tabel 1) is 
gekozen om geen wash-out in te bouwen. de onderzoekers gingen ervan uit dat 
het effect van een hoger of lager zoutgehalte uitgewerkt was als het effect van het 
zoutgehalte aan het eind van een volgende periode gemeten werd.3 Als carry-over 
effecten niet kunnen worden voorkomen door een wash-out of interventieperiode 
van voldoende duur, raden wij aan om voor een parallelle-groep studie te kiezen.
periode effecten en het nut van randomiseren
patiënten veranderen over de tijd. Gemiddeld nemen bloeddruk en gewicht bij-
voorbeeld toe met de leeftijd.7, 8 deze ‘vaste’ verandering in de tijd wordt het 
periode effect genoemd	en	kan	de	resultaten	van	een	cross-over	studie	beïnvloe-
den. dit zou in de dAsH trial (Tabel 1) kunnen gebeuren als alle deelnemers de 
verschillende zoutgehaltes in dezelfde volgorde zouden krijgen (bijvoorbeeld: 
hoog-, gemiddeld- en laag zoutgehalte). een bloeddrukverlagend effect van de 
lagere zoutgehaltes zou dan verstoord kunnen worden door de ‘vaste’ bloeddruk-
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verhoging in de tijd. de onderzoekers zouden dan onterecht concluderen dat er 
geen	bloeddrukverlagend	effect	is	van	een	lager	zoutgehalte.	Beïnvloeding	door	
het periode effect wordt voorkomen door aan het begin van de studie te randomi-
seren voor de volgorde van de behandelingen.
uitval van deelnemers
net als bij parallelle-groep studies is het bij cross-over studies van belang dat zo 
min mogelijk deelnemers uitvallen tijdens de studie en dat wordt bijgehouden 
wat de redenen van uitval zijn. voor een cross-over studie heeft de uitval van 
deelnemers echter grotere gevolgen dan voor een parallelle-groep studie. dit 
komt doordat de vergelijking van interventies plaatsvindt binnen individuen. deze 
vergelijking kan niet plaatsvinden als een deelnemer uitvalt voordat hij alle inter-
venties gehad heeft. Aangezien elke deelnemer in een cross-over studie relatief 
meer bijdraagt aan de precisie (power) van de studie dan een deelnemer in een 
parallelle groep studie, verliest een cross-over studie ook sneller zijn precisie bij 
uitval van deelnemers dan een parallelle-groep studie. Als er een grote kans is op 
uitval van deelnemers, bijvoorbeeld door belastende metingen of bijwerkingen 
van de behandeling, kan beter gekozen worden voor een parallelle-groep studie.
Aandachtspunten voor deelnemers
voor deelnemers aan een cross-over studie kan het een nadeel zijn dat de tijd die 
zij doorbrengen in het onderzoek tweemaal zo lang is als in een parallelle-groep 
studie. Met een wash-out periode is dit nog langer. Terwijl in een parallelle-groep 
studie patiënten meestal maar 50% kans hebben om gerandomiseerd te worden 
voor de nieuwe behandeling, krijgt elke deelnemer in een cross-over studie gega-
randeerd de experimentele behandeling. dit kan een nadeel zijn omdat deelne-
mers in een cross-over studie alle interventies en metingen moeten ondergaan. 
Aan de andere kant kan het juist prettig zijn voor deelnemers om te weten dat 
ze in ieder geval een periode de experimentele behandeling krijgen. Mogelijk is 
de bereidheid tot deelname hierdoor groter bij een cross-over studie dan bij een 
studie met parallelle groepen. de voor- en nadelen voor de deelnemers hangen 
dus af van de bestudeerde interventie en de cross-overopzet.
WAnneer KAn een cross-over sTudie GebruiKT Worden?
in een cross-overstudie moet de interventie een tijdelijk effect hebben, waarbij 
na het staken van de interventie de patiënt weer terugkeert in de staat van vóór 
het begin van de interventie. Hierbij valt te denken aan aandoeningen die een 
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chronisch beloop hebben en de behandeling geen genezing brengt maar gericht is 
op symptoombestrijding of op vertraging van het ziekteproces. voorbeelden zijn 
hypertensie, astma, reuma, migraine, epilepsie en diabetes mellitus.
in een cross-over studie moet de uitkomst van de bestudeerde interventie op 
relatief korte termijn te meten zijn, bijvoorbeeld bloeddruk, aanvalsfrequentie bij 
epilepsie, longfunctie of pijn scores. cross-over studies zijn niet geschikt voor het 
bestuderen van interventies waarbij een lange follow-up nodig is om de uitkomst 
te meten. ook zijn cross-over studies niet geschikt om interventies te bestuderen 
met een blijvend effect, zoals genezing of overlijden. de patiënt keert dan immers 
niet in zijn oorspronkelijke staat terug. Alle voor- en nadelen van cross-over studies 
zijn samengevat in tabel 2. Kortom, een cross-overstudie vormt een alternatief 
voor een studie met parallelle groepen als: (a) een stabiele chronische aandoening 
bestudeerd wordt; (b) de bestudeerde interventie een tijdelijk effect heeft (geen 
genezing of overlijden); (c) het carry-over-effect kan worden vermeden door een 
uitwasperiode of interventieperiodes van voldoende duur; (d) een laag percentage 
uitval van deelnemers verwacht wordt; (e) voor deelnemers een langere studieduur 
acceptabel is.
AnAlyse
in een cross-overstudie is er sprake van herhaalde (gepaarde) metingen bij 1 indi-
vidu. de meest gebruikte methode om data uit een cross-overstudie weer te geven 
is een tabel waarin de uitkomst in kolommen gesorteerd is op de behandeling, 
















uitgesplitst naar de volgorde waarvoor deelnemers gerandomiseerd zijn.1 Met een 
gepaarde t-test kan het verschil in bloeddruk tussen de 2 interventies (inname 
‘s ochtends vs. ‘s avonds) statistisch getest worden. in de praktijk is echter vaak 
sprake van ontbrekende waarden en worden meerdere metingen verricht in 2 
of meer periodes. een gepaarde t-toets of variantieanalyse (AnovA) is dan niet 
geschikt, omdat deze testen individuen met ontbrekende waarden niet meenemen 
in de analyse. voor analyse van cross-overstudies wordt daarom meestal gebruik 
gemaakt van analysemethoden voor herhaalde metingen (‘mixed models’).9 Met 
deze methoden worden individuen van wie waarden ontbreken, wél meegenomen 
in de analyse en kunnen ook periode-effecten geanalyseerd worden.
conclusie
in sommige gevallen zijn cross-over studies een goedkoop en efficiënt alternatief 
voor parallelle-groep studies. de belangrijkste voordelen zijn dat maar een kwart 
tot de helft van het aantal patiënten nodig is en dat de onderzochte behandelin-
gen vergeleken worden bij de individuele patiënt. een cross-over studie vormt een 
alternatief voor een parallelle-groep studie als een stabiele chronische aandoening 
bestudeerd wordt en de bestudeerde interventie een tijdelijk effect heeft (geen 
genezing, geen overlijden). Het is van belang dat het carry-over effect zoveel mo-
gelijk wordt vermeden door een wash-out of interventieperiodes van voldoende 
duur. voor deelnemers moet de langere studieduur van een cross-over studie ac-
ceptabel zijn. de kans op uitval van deelnemers moet laag zijn omdat uitval voor 
cross-over studies grotere negatieve gevolgen heeft dan voor parallelle-groep stu-
dies. Als aan deze voorwaarden wordt voldaan is een cross-over studie voordeliger 
en efficiënter dan een parallelle-groep studie.
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Aspirin intake at bedtime: does 
it lower blood pressure and 
morning platelet reactivity 
in patients with stable 
cardiovascular disease? A 
randomized cross-over trial
T.n. bonten, J.d. snoep, W.J. Assendelft, J.J. Zwaginga, J. 





To evaluate whether intake of low-dose aspirin at bedtime, compared with intake 
on awakening, reduces 24-hour ambulatory blood pressure and morning platelet 
reactivity.
Methods and results
in this randomized open-label cross-over trial, 290 patients were randomized to 
take 100mg aspirin on awakening or at bedtime during two periods of 3 months. 
At the end of each period 24-hour blood pressure and morning platelet reactivity 
was measured. The primary analysis population comprised 263 (blood pressure) 
and 133 (platelet reactivity) patients. Aspirin intake at bedtime did not reduce 
blood pressure compared with intake on awakening (difference systolic/diastolic: 
-0.1 [95% ci: -1.0; 0.9] / -0.6 [95% ci: -1.2; 0.0] mmHg). platelet reactivity during 
morning hours was reduced with bedtime aspirin intake (difference: -22 Aru [95% 
ci -35; -9]).
conclusions
This study showed that the intake of aspirin at bedtime compared with intake on 
awakening does not reduce blood pressure of patients taking aspirin for cardio-
vascular disease prevention. However, bedtime aspirin reduced morning platelet 
reactivity. Future studies are needed to assess the impact of this promising simple 
intervention on the excess of cardiovascular events during the high risk morning 
hours.
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inTroducTion
cardiovascular disease (cvd) is still a leading cause of mortality and morbidity 
worldwide.1, 2 one of the most important modifiable risk factors for cvd is blood 
pressure. even small reductions of blood pressure significantly decrease the risk 
of myocardial infarction and stroke.3 However, almost half of the patients with 
hypertension remain uncontrolled despite blood pressure lowering medication.4 
Thus, simple interventions to improve blood pressure control are needed.
Aspirin traditionally was assumed to have no effect on blood pressure5, but in 
recent studies aspirin intake at bedtime compared with intake on awakening con-
siderably reduced blood pressure.6-11 Additionally, we previously found that aspirin 
intake at bedtime compared with on awakening reduced plasma renin activity and 
cortisol, dopamine and norepinephrine excretions over 24 hours.12 However, all 
previous studies included healthy subjects, pregnant women or patients with mild 
hypertension.6-11, 13 if the effect of bedtime aspirin intake on blood pressure also 
holds for patients who already use aspirin for cvd prevention, simply changing the 
time of intake from awakening to bedtime could substantially reduce their risk for 
recurrent cardiovascular events.
Furthermore, platelet aggregation peaks during morning hours, which is thought 
to contribute to the observed peak of cvd from 6 to 12 AM.14, 15 due to its short 
half-life, aspirin only inhibits the platelets that are present at the time of intake, 
while new platelets are released at a rate of 10% per day in healthy subjects.16, 17 
Thus, just before each aspirin intake, these newly released platelets are uninhibited 
and can induce platelet aggregation. However, it is desirable to achieve optimal 
platelet aggregation inhibition particularly during those high risk morning hours. 
As already suggested by previous authors, intake of aspirin at bedtime might at-
tenuate the morning peak of platelet reactivity, but this was never evaluated in a 
clinical trial.18, 19
To assess whether aspirin intake at bedtime compared with intake on awakening 
reduces blood pressure and morning platelet reactivity we conducted a random-
ized cross-over trial in patients using low-dose aspirin for prevention of cvd.
MeTHods
study population
patients between 18-75 years of age using aspirin for secondary prevention of 
cvd were recruited from general practitioner (Gp) practices around leiden, the 
netherlands. subjects with a baseline blood pressure (bp) of <120/70 or >160/100 
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mmHg were excluded. Additionally, subjects were excluded if they used other anti-
platelet drugs than aspirin or had changed any antihypertensive medication in the 
3 months before baseline to guarantee stability of cvd and blood pressure before 
entry into the study. other exclusion criteria were regular use of non-steroidal anti-
inflammatory drugs (nsAids), employment as shift worker, evidence of secondary 
arterial hypertension (e.g. pheochromocytoma) and pregnancy.
study design
This prospective, randomized, open-label, blinded endpoint (probe), 2-period 
crossover study was conducted at a single center in the netherlands and registered 
at www.clinicaltrials.gov/ct2/show/ncT01379079. benefits of the probe design and 
its validity for studies measuring ambulatory blood pressure have been previously 
documented.20 The study was conducted in accordance with the declaration of 
Helsinki, approved by the leiden university Medical center (luMc) ethics commit-
tee and all subjects gave written informed consent. randomization was performed 
with a computer-generated randomization code by an independent person at 
the department of clinical epidemiology of the luMc and was inaccessible to 
the investigators. eligible subjects were randomized (1:1 ratio) to take aspirin on 
awakening followed by aspirin at bedtime or the opposite order during two in-
tervention periods of 3 months. The two intervention periods were not separated 
by a wash-out period, because withholding aspirin to the included patients was 
considered unethical. The duration of each intervention period was analogous to 
previous studies.9-11 All subjects received 100 mg effervescent aspirin (carbasalate 
calcium, vemeda Manufacturing, the netherlands). At the end of each interven-
tion period, subjects visited the research site for two consecutive days. At day 1, 
24-hour ambulatory blood pressure measurement (AbpM) was started between 
8-12 AM and subjects took aspirin at the same time as in the preceding 3 months. 
At day 2, subjects refrained from taking aspirin in the morning, AbpM was ended 
and blood was drawn. The time of AbpM start at day 1 and blood draw at day 2 
was similar for each participant at each visit.
Measurements
Blood pressure
At baseline, bp was measured by an automatic device (Mobil-o-Graph nG device; 
ieM GmbH, Germany) every 2 minutes in seated position after 10 minutes of rest. 
The average of 6 readings was used to determine baseline blood pressure. As the 
primary endpoint, AbpM was performed during participants normal daily routine 
with a validated and calibrated Mobil-o-Graph nG device (ieM GmbH, Germany). 
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Measurements started between 8-12AM and the same device was used at each visit. 
The bp cuff was adjusted to the arm circumference and worn on the non-dominant 
arm. systolic and diastolic bp were automatically measured every 20 minutes during 
the day and every 30 minutes during the night for 24 consecutive hours, with the 
screen turned off to blind subjects for bp readings. Activities, bed- and awakening 
times were recorded in a diary. AbpM was considered valid if at least 70% of the 
measurements were valid, sleep time during AbpM was between 6 and 12 hours 
and data were not missing for an interval of more than 2 hours.
Platelet reactivity
As a secondary endpoint, platelet reactivity was measured during morning hours 
(between 8 and 12 AM). At the morning of blood sampling subjects refrained from 
taking aspirin. blood was sampled without stasis from the antecubital vein and 
platelet reactivity was measured with the verifynow® Aspirin Assay (Accumetrics, 
san diego, usA).21 According to manufacturer’s instructions, platelet reactivity was 
measured between 30 minutes and 4 hours after the blood draw.
Questionnaires, compliance and patient preference
subjects completed a questionnaire to assess eligibility criteria, medical history, 
medication use and chronobiological rhythm at baseline. Missing information 
was completed with the use of general practitioner or pharmacy records. At each 
follow-up visit, side effects and change in other medication were registered by 
questionnaires. subjects were instructed to take aspirin within 1 hour after awak-
ening or 1 hour before bedtime. compliance was assessed and optimized with 
electronic pill boxes (evalan, Amsterdam, the netherlands), which registered the 
time of intake and sent an sMs text message if subjects were non-compliant. Ad-
ditionally, a pill count was performed at each visit. subjects were instructed not to 
change timing of co-medication, which was checked with questionnaires at each 
follow-up visit. pre-randomization timing of aspirin use and patient preference 
after study completion was assessed by questionnaires.
statistical analyses
To detect an inter-individual difference of 3 mmHg in blood pressure with 80% 
power at a 5% significance level, we calculated a required sample size of 250 
patients. For this calculation we assumed an intra-individual standard deviation 
of 12.9 mmHg, as derived from a previous study.12 estimating a drop-out of 10% 
and invalid AbpM of 5%, we randomized 290 subjects. As planned on beforehand, 
platelet reactivity was measured in the first 160 patients, yielding a power of 90% 
to detect a difference of 17 Aru at a 5% significance level. For this calculation 
38 chapter 3
we used an intra-individual standard deviation of 46.85 Aru, as derived from 
a previous study.22 continuous characteristics are described as mean ± standard 
deviation(sd) if normally distributed or as median (interquartile range [iQr]) if 
not normally distributed. categorical variables are expressed as numbers (percent-
ages). For analysis, we edited AbpM values according to conventional criteria to 
remove measurement errors and outliers. because the sampling frequency was 
denser during the day (3x/hour) than during the night (2x/hour), we calculated a 
weighted overall mean bp, as suggested previously23:
 
(mean day BP ∗ nr day measurements) + (mean night BP ∗ nr night measurements) 
nr day measurements + nr night measurements
 
sum day or night measurements
nr day or night measurements
 
Mean day- and night bp was calculated as:
For these calculations, the start of day- and night times was obtained from the 
AbpM diaries.
The primary endpoint was assessed in a primary- and secondary analysis popula-
tion. The primary analysis population included all subjects who were randomized 
and completed measurements of the endpoints. The secondary analysis population 
excluded subjects with one or more invalid AbpM, change of antihypertensive 
medication, or compliance <90%. paired t-tests were performed to analyze day-, 
night- and overall mean bp after intake of aspirin on awakening and at bedtime. 
Additionally, we used linear mixed models to assess the treatment effect and pos-
sible period or carry-over effects. subgroup analyses were pre-specified for users of 
beta-blockers, inhibitors of the renin-angiotensin system (users versus non-users), 
users of no- versus 1 or more blood pressure lowering drugs and subjects with 
baseline systolic bp of >140 versus ≤140 mmHg.
The secondary endpoint platelet reactivity was analysed with a paired t-test and 
linear mixed models. subjects who forgot to take aspirin on the day before platelet 
reactivity measurements (n=3) were excluded from analysis. subgroup analyses 
were pre-specified for diabetic subjects, current smokers (yes versus no) and mean 
platelet volume (Mpv) values (divided into quartiles). Although not pre-specified, 
an additional subgroup analysis for body mass index (bMi) was performed, because 
obesity, as a marker for metabolic syndrome, may be associated with platelet re-
activity.24
side effects and patients’ preferences were analysed descriptively and using 
Mcnemar’s test. All analyses were performed in spss 20.0 (ibM corp., usA) and 
were 2-sided, with a level of significance of 0.05.
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resulTs
study population and compliance
between June 2011 and december 2012, 3479 subjects were screened at 30 Gp 
practices, of whom 1704 did not meet inclusion criteria, primarily because of age 
>75 years (n=1080) and use of other platelet inhibiting drugs (n=386). A further 
1182 subjects did not respond or declined to participate and 303 were excluded 
for other reasons (Figure 1). A total of 290 subjects were randomized, and baseline 
characteristics were similar between groups (Table 1). The study follow-up was 
discontinued by 26 subjects, primarily because study participation was too aggra-
vating (18/26; 70%). The primary- and secondary analysis populations comprised 
263 and 150 subjects, respectively, for assessment of the primary endpoint. Mea-
surements for the secondary endpoint platelet reactivity were complete for 136 
 
Assessed for eligibility (n=3479) 
Not included (n=3189) 
 Did not meet inclusion criteria (n=1704) 
 Declined to participate (n=655) 
 Did not respond to invitation (n=527) 
 Excluded for other reasons* (n=303) 
Randomized (n=290) 
Allocated to morning intake (n=145) Allocated to evening intake (n=145) 
Visit 2 (3 months) 
Withdrawal of consent  (n=6) 
 Participation too aggravating (n=4) 
 Dyspepsia (n=2) 
Crossed over to evening intake (n=139) 
Visit 2 (3 months) 
Withdrawal of consent  (n=9) 
 Participation too aggravating (n=7) 
 Stopped aspirin use (n=2) 
Crossed over to morning intake (n=136)
Visit 3 (6 months) 
Withdrawal of consent  (n=5) 
 Participation too aggravating (n=4) 
 Stopped aspirin use (n=1) 
Completed 6 month study period (n=134)
Allocation 
Study start: September 2011 
Study  completion: September 2013 
Visit 3 (6 months) 
Withdrawal of consent  (n=6) 
 Participation too aggravating (n=3) 
 Stopped aspirin use (n=3) 
Completed 6 month study period (n=130)
Secondary analysis population (n=73) 
 Excluded (n=61) 
 Invalid ABPM visit 1 and/or visit 2 (n=30) 
 Change of blood pressure lowering drugs (n=8)  
 Compliance during whole study < 90% (n=23) 
Primary analysis population  
 Primary endpoint: ABPM (n=129†) 
 Secondary endpoint: Platelet reactivity (n=65) 
Secondary analysis population (n=77) 
 Excluded (n=52) 
 Invalid ABPM visit 1 and/or visit 2 (n=27) 
 Change of blood pressure lowering drugs (n=6)  
 Compliance during whole study < 90% (n=19) 
Primary analysis population  
 Primary endpoint: ABPM (n=134) 
 Secondary endpoint: Platelet reactivity (n=71) 
Follow-up 
Analysis populations 
Figure 1 – patient flow. AbpM: ambulatory blood pressure measurement. * other reasons: 
stopped aspirin use before inclusion, not able to participate in clinical trial as judged by gen-
eral practitioner, changed address, not speaking dutch language. † 1 subject refused AbpM at 
the last follow-up visit.
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subjects. compliance as measured by electronic pill boxes and pill count was high, 
and similar with aspirin intake on awakening (99% [97 to 100%] and 100% [100 
to 100%], respectively) and intake at bedtime (98% [94 to 100%] and 100% [100 
to 100%]).
Table 1. baseline clinical characteristics of randomized study participants (n=290)*
Awakening – Bedtime 
group (n=145)
Bedtime – Awakening 
group (n=145)
sex (M/F) 106/39 106/39
Age (yr) 64±7 64±7
current smokers 21 (15) 28 (19)
body mass index (kg/m2) 28.4±4.7 28·1±4.6
systolic blood pressure (mmHg) 137±10 137±10
diastolic blood pressure (mmHg) 88±8 88±8
diabetics 17 (12) 14 (10)
cardiovascular history
Myocardial infarction 53 (37) 59 (41)
stable angina pectoris 59 (41) 61 (42)
stroke/Transient ischemic attack 28 (19) 23 (16)
Atrial fibrillation 14 (10) 13 (9)
peripheral artery disease 12 (8) 9 (6)
other† 3 (2) 1 (1)
Aspirin use at baseline
on awakening 106 (73) 100 (69)
duration (years) 6 (3-11) 6 (4-14)
Medication use
number of blood pressure 
lowering drugs§
2 (1-2.5) 2 (1-3)
β-blockers 74 (51) 80 (55)
Ace-inhibitors 60 (41) 55 (38)
Angiotensin ii inhibitors 37 (26) 33 (23)
calcium antagonists 29 (20) 27 (19)
diuretics 37 (26) 46 (32)
lipid lowering drugs 116 (80) 123 (85)
*  continuous values are presented as means ± standard deviation (sd) or medians + inter-
quartile range if not normally distributed. categorical values are presented as number (%).
† other cardiovascular disease: heart valve disease (n=3), myelodysplastic syndrome (n=1).
§  blood pressure lowering drugs: β-blockers, α-blockers, ace-inhibitors, angiotensin-ii inhibi-
tors, calcium antagonists, thiazide and loop diuretics, nitrates (daily use).
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Bedtime 24-hour mean = 127.1
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Figure 2 – effect of low-dose aspirin intake at bedtime compared with intake on awakening 
on 24-hour ambulatory blood pressure profile in the primary analysis population (n=263). A. 
systolic blood pressure. B. diastolic blood pressure. each graph shows hourly means and stan-
dard errors of blood pressure measured after 3 months of low-dose aspirin intake on awaken-
ing (continuous blue line) and 3 months of low-dose aspirin intake at bedtime (dashed red line). 
Hours on the x-axis refer to hours after awakening from nocturnal sleep, as recorded in diaries 
during AbpM. The shaded area represents the average nocturnal period for all subjects.
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blood pressure
The circadian 24h AbpM profile after 3 months aspirin intake on awakening and 3 
months intake at bedtime is depicted in Figure 2. The mean (sd) 24-hour systolic 
and diastolic blood pressures were 127 (12) and 79 (9) mmHg with aspirin intake 
on awakening, whereas this was 127 (12) and 78 (8) with aspirin at bedtime. This 
resulted in differences of -0.1 mmHg (95% confidence interval (ci) -1.0 to 0.9) 
and -0.6 mmHg (ci -1.2 to 0.0). Furthermore, systolic and diastolic blood pressures 
during day- and nighttime did not differ by the timing of aspirin intake (Table 
2). Mixed model analysis showed the same results and no evidence for carry-over- 
or period effects (data not shown). Additionally, the findings among subgroups 
of subjects using or not using β-blockers, angiotensin inhibitors, blood pressure 
lowering drugs in general or subjects with baseline office bp >140 or ≤140 mmHg 
were similar to the overall results (Table 3). Finally, in the secondary analysis, 
comprising only patients with valid AbpM at both visits who did not change their 
antihypertensive medication between visit 2 and 3 and were ≥90% compliant as 
registered with electronic pill boxes, aspirin intake at bedtime was not associated 
with a reduction of mean 24-hour blood pressure or day- and night time blood 
pressure (Appendix table 1).
platelet reactivity
Three subjects forgot to take aspirin on the day before platelet reactivity measure-
ments, and were excluded from this analysis. in the remaining 133 subjects, aspirin 
intake at bedtime reduced morning platelet reactivity (mean difference -22 Aru 
[95% ci -35 to -9]; p=0.001; Figure 3). subgroup analysis showed that, besides in 
subjects with diabetes, aspirin intake at bedtime reduced platelet reactivity in all 
subgroups (Table 4).
Table 2. Mean 24-hour, day- and night ambulatory blood pressure values (mmHg) according to 
time of aspirin administration in the primary analysis population (n=263)
Aspirin on 
awakening
Aspirin at bedtime mean difference 
(bedtime – awakening)
[95% ci]*
24-hour sbp 127 ± 12 127 ± 12 -0.1 [-1.0 to 0.9]
24-hour dbp 79 ± 9 78 ± 8 -0.6 [-1.2 to 0.0]
day sbp 131 ± 12 131 ± 12 0.0 [-1.0 to 1.0]
day dbp 82 ± 9 81 ± 9 -0.6 [-1.2 to 0.1]
night sbp 117 ± 15 117 ± 14 -0.1 [-1.4 to 1.1]
night dbp 69 ± 10 69 ± 9 -0.4 [-1.2 to 0.3]
*Mean difference and 95% ci obtained with paired t-tests. values are mean ± standard devia-
tion. sbp: systolic blood pressure; dbp: diastolic blood pressure; ci: confidence interval
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Figure 3 – effect of low-dose aspirin intake at bedtime versus on awakening on morning plate-
let reactivity. Filled bars represent verifynow platelet reactivity values after aspirin intake on 
awakening. dashed bars represent values after aspirin intake at bedtime.
Table 3. subgroup analysis of the effect of Aspirin intake on awakening or at bedtime on mean 
24-hour blood pressure




no 121 -0.3[-1.7 to 1.2] / -0.8[-1.7 to 0.2]
yes 142 0.1[-1.1 to 1.3] / -0.3[-1.2 to 0.4] 0.80
Angiotensin inhibitor use‡
no 106 -0.2[-1.5 to 1.0] / -1.0[-1.9 to -0.2]
yes 157 0.0[-1.3 to 1.4] / -0.2[-1.0 to 0.6] 0.68
blood pressure lowering drugs 
use§
no 51 0.3[-1.5 to 2.1] / -1.3[-2.7 to 0.0]
yes 212 -0.2[-1.2 to 0.9] / -0.4[-1.0 to 0.3] 0.78
baseline systolic office blood pressure
>140 mmHg 92 0.9[-0.8 to 2.5] / 0.0[-1.1 to 1.2]
≤140 mmHg 171 -0.6[-1.7 to 0.6] / -0.9[-1.6 to -0.2] 0.14
All blood pressure differences are depicted as systolic[95% ci] / diastolic[95% ci] blood pres-
sure, in mmHg; *Mean difference and 95% confidence interval (ci) obtained from paired t-test 
within each subgroup; †p-value for interaction obtained from linear mixed model analysis; 
‡Angiotensin receptor inhibitors: use of ace-inhibitors and/or angiotensin-2-inhibitors. § blood 
pressure lowering drugs: β-blockers, α-blockers, ace-inhibitors, angiotensin-ii inhibitors, cal-
cium antagonists, thiazide and loop diuretics, nitrates (daily use).
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side effects and patient preference
Three subjects did not complete the study due to side effects (supplemental table 
2). of these subjects, 2 developed dyspepsia after the switch from aspirin intake in 
the evening (before study entry) to intake on awakening in the first study period, 
and 1 developed headache after the switch from intake on awakening to intake at 
bedtime during study follow-up. The frequency of well-known aspirin side effects 
(dyspepsia, nausea, heartburn) was similar between aspirin intake on awakening 
and at bedtime (Appendix table 3).
At baseline 206/290 (71%) of the subjects took aspirin on awakening. After 
completion of the study, 53/264 (20%) preferred to switch to another time of 
aspirin intake than prior to study entry. A total of 32/264 (12%) switched from 
intake on awakening to intake at bedtime and 21/264 (8%) from at bedtime to on 
awakening. so, no clear patient preference was present for time of intake.
Table 4. subgroup analysis of the effect of low-dose aspirin intake on awakening or at bedtime 
on morning platelet reactivity (n=133)









no 115 455 ± 61 429 ± 50 -26 [-40 to -13]
yes 18 455 ± 55 463 ± 71 8 [-34 to 50] 0.03
bMi (kg/m2)‡
18.5 – 25 37 452 ± 52 425 ± 52 -27 [-47 to -8]
25 – 30 60 454 ± 66 439 ± 58 -15 [-36 to 7] 0.41§
≥ 30 36 459 ± 58 432 ± 51 -27 [-53 to -1] 0.94§
smoking
no 110 453 ± 60 433 ± 57 -20 [-35 to -5]
yes 23 463 ± 61 433 ± 43 -29 [-58 to -1] 0.77
Mean platelet volume (fl), quartile (range)
1 (9.1 – 10.1) 441 ± 57 424 ± 57 -16 [-93 to 9]
2 (10.2 – 10.6) 457 ± 60 441 ± 55 -10 [-46 to 25] 0.77§
3 (10.7 – 11.3) 471 ± 68 443 ± 55 -25 [-53 to 4] 0.49§
4 (11.4 – 12.6) 445 ± 48 427 ± 59 -18 [-45 to 9] 0.98§
All platelet reactivity values are depicted in Aspirin reaction units (Aru)±standard deviation. 
Higher Aru represents higher platelet reactivity.
* Mean difference and 95% ci obtained from paired t-test within each subgroup
† p-value for interaction obtained from linear mixed model analysis
‡ bMi classified according to World Health organizations’ classification of obesity
§ p-value for interaction with the first group as reference group
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discussion
in this large cross-over trial among patients using low-dose aspirin for cvd pre-
vention, 24-hour blood pressure did not differ between aspirin intake at bedtime 
and intake on awakening. However, aspirin intake at bedtime was associated with 
lower morning platelet reactivity.
comparison with previous studies
The finding that aspirin intake at bedtime compared with intake on awakening does 
not reduce blood pressure is in contrast with previous studies, mostly from a single 
source in this field.6-11, 13, 25 This may be explained by differences in study popula-
tions. First, previous studies included subjects who did not use blood pressure low-
ering drugs such as β-blockers or inhibitors of the renin-angiotensin-aldosterone 
system- (rAAs). This is an important difference, because the mechanism behind 
the time-dependent effect of aspirin on blood pressure was previously related to 
a reduction in renin-angiotensin-aldosterone system- (rAAs) and catecholamine 
activity over 24 hours.12 However, in our subgroup analyses, we did not find an 
effect in both users and non-users of β-blockers or rAAs-inhibitors. even in the 
subgroup who did not use any blood pressure lowering drugs, there was no effect. 
our findings corroborate those of an earlier study which also did not find a blood 
pressure lowering effect of bedtime aspirin intake among treated hypertensive 
patients.26 second, patients in all previous studies did not use aspirin before study 
entry. in contrast, all patients in our study had a medical indication for aspirin use 
and had used aspirin for median 6 years. it is possible that the time-dependent 
effect of aspirin on blood pressure weakens over time because of increased arte-
rial stiffening.27 However, a potential blood pressure lowering effect of bedtime 
aspirin intake would only be clinically relevant in patients already using aspirin for 
cvd prevention, and we are the first in this field to include this clinically relevant 
patient group.
The circadian rhythm of platelet reactivity and its relation with the morning 
peak of cardiovascular events has been thoroughly studied.15, 28 previous authors 
suggested that platelet inhibition during these high risk morning hours could be 
optimized by aspirin intake at bedtime.18, 19 However, to the best of our knowledge, 
this has never been evaluated in a clinical trial. our study suggests that morn-
ing platelet reactivity can be reduced by taking aspirin at bedtime instead of on 
awakening. This effect was homogeneously present in all subgroups, except in 
diabetic subjects. However, the size of this subgroup was too small (n=18) to rule 
out any effect in diabetic patients. The reduction of platelet reactivity during the 
vulnerable morning hours might be beneficial for patients with cvd, who have 
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higher platelet turnover and of which in 25% platelet reactivity is inadequately 
inhibited 24 hours after aspirin intake.29, 30 previous authors suggested that twice 
daily dosing of aspirin is yields more effective platelet inhibition over the whole 
day in selected patient populations with high platelet turnover (e.g. diabetic 
patients).31-33 Although this seems valuable for selected patient populations, we 
would not recommend twice daily dosing for all cvd patients, because twice daily 
dosing could result in more side effects and less compliance.34, 35
clinical interpretation
it has been shown that the risk for recurrent cardiovascular events is increased 
in patients with higher verifynow-aspirin platelet reactivity values.36, 37 stable 
cvd patients with platelet reactivity >550 Aru had an absolute risk of 15.6% for 
developing the composite cardiovascular endpoint, whereas this was only 5.3% 
in patients with Aru values <550.37 in another study, the absolute risk for the 
primary endpoint (all-cause death and recurrent cardiovascular events) was 13.3% 
in patients >454 Aru and 5.9% in patients <454 Aru.36 These observational studies 
suggest that already a modest reduction in platelet reactivity could result in clinical 
benefit for patients with cvd.
because the cvd morning peak is a multifactorial process, we do not expect that 
bedtime aspirin would abolish the cvd morning peak completely.38 still, given the 
high prevalence of cvd, already a modest reduction of the morning peak would 
lead to a large absolute benefit. For example, 280.000 recurrent cardiovascular 
events occur in the united states (us) every year, and thus on average 767 each 
day.1 With the known excess of 40% during the morning hours (6-12 AM)39, this 
would mean that 241 events occur from 6 to 12 AM, and 526 during the rest of the 
day. if aspirin intake at bedtime would reduce this morning peak by 20%, it would 
lead to an absolute reduction of 4853 recurrent events each year in the us alone. 
in summary, switching to bedtime aspirin intake is a simple and possible effective 
intervention, but future clinical trials should evaluate whether this intervention 
indeed translates in a reduction of recurrent cardiovascular events.
strengths and limitations
The major strength of our study is that we used a cross-over design, which yields 
high statistical power and enables comparison of treatment effects within each 
patient. Furthermore, this is the first study in this field which registered the actual 
time of aspirin intake by electronic pill boxes, which is of major importance to 
study time-dependent effects.
The main limitation of our study is that only 150/263 (57%) patients complied 
perfectly with the study protocol. This was mainly due to invalid AbpM (n=57) or 
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compliance of less than 90% within the prespecified time of intake (n=42). How-
ever, sensitivity analysis among patients with complete follow-up and compliance 
revealed exactly the same results. importantly, the statistical power of this second-
ary analysis was still adequate, as reflected by the narrow confidence intervals in 
our secondary analysis (supplemental table 1). Another limitation could be the 
open-label design of this study. However, benefits and validity of the open-label 
probe design have been previously documented and we do not think that the 
design influenced the objective AbpM and platelet reactivity measurements as 
endpoints.20
regarding platelet reactivity measurements, it is a limitation that we measured 
platelet reactivity at only one time point during the morning, although comparabil-
ity within subjects was optimized by drawing blood at the same time at each visit. 
yet, it is possible that the peak of platelet reactivity is shifted to another time of 
the day, which is currently being investigated by our group (www.clinicaltrials.gov/
ct2/show/ncT01900639). However, a shift of the platelet reactivity peak away from 
the morning hours to another time of the day would still be beneficial, because 
other triggers of acute vascular events present during the high risk morning hours 
(e.g. morning blood pressure surge, rise of cortisol and catecholamines) are absent 
during the rest of the day.38
conclusions
previous studies suggested that low-dose aspirin taken at bedtime reduces blood 
pressure. However, this surprising phenomenon was never studied in patients using 
aspirin for cvd prevention. This study showed that the intake of aspirin at bedtime 
compared with intake on awakening does not reduce blood pressure in patients 
with stable cvd using low-dose aspirin on a daily basis. yet, bedtime aspirin intake 
did reduce platelet reactivity during morning hours. Future studies are needed to 
assess the impact of this simple intervention on the excess of cardiovascular events 
during morning hours.
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The risk of acute cardiovascular events is highest during morning hours, and plate-
let activity peaks during morning hours. The effect of the timing of aspirin intake 
on circadian rhythm and morning peak of platelet reactivity is not known.
Methods and results
A randomized open-label cross-over trial in healthy subjects (n=14) was conducted. 
participants used acetylsalicylic acid (80mg) for two periods of two weeks on 
awakening and at bedtime, or the opposite order. At the end of both periods, 
participants were admitted and blood was drawn every 3 hours to measure 
cyclo-oxygenase-1 (coX-1)-dependent (verifynow-Aspirin; serum Thromboxane 
b2 [sTxb2]) and coX-1-independent (flow cytometry surface cd62p expression; 
microaggregation) platelet activity.
Mean verifynow platelet reactivity over the whole day was similar with intake 
on awakening and at bedtime (mean difference: -9 [95% confidence interval (ci) 
-21 to 4]). However, the morning increase in coX-1-dependent platelet activity 
was more efficiently reduced by intake of aspirin at bedtime compared with on 
awakening (mean difference verifynow: -23 Aspirin reaction units [ci -50 to 4]; 
sTxb2: -1.7 ng/ml [ci -2.7 to -0.8]). coX-1-independent assays were not affected by 
aspirin intake or its timing.
conclusions
low-dose aspirin taken at bedtime compared with intake on awakening reduces 
coX-1-dependent platelet reactivity during morning hours in healthy subjects. 
Future clinical trials in larger patient groups are required to investigate whether 
simply switching to aspirin intake at bedtime reduces the risk of cardiovascular 
events during the high risk morning hours and offers an overall benefit.
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inTroducTion
low-dose aspirin is one of the most used drugs worldwide, and a cornerstone in 
the prevention of cardiovascular disease (cvd).1 it reduces the risk of recurrent 
cvd with about 25%.2 Although not supported by evidence, aspirin is usually taken 
on awakening. However, it may be more beneficial to take aspirin at bedtime. 
Aspirin’s preventive action is based on the inhibition of platelet aggregation and 
the formation of arterial thrombi, which plays an important role in the pathogen-
esis of acute cvd.3, 4 platelet aggregation and activation surface markers follow a 
circadian rhythm, with a peak between 6 AM to noon.5, 6 This might play a role in 
the observed peak of acute cvd during morning hours, which is present in patients 
with- and without previous cvd.7-10 Moreover, patients with a myocardial infarc-
tion during morning hours have larger infarct size than those with events during 
the rest of the day, which has a worse prognosis.11, 12 Therefore, it could be useful 
to develop interventions specifically aimed at reducing the morning peak of cvd.
due to its short half-life, aspirin only inhibits platelets which are present at the 
time of intake, while new platelets are released at a rate of 10%/day in healthy 
subjects.13, 14 This turnover rate is even higher in patients with atherosclerotic dis-
ease.15, 16 newly released platelets are more reactive and are uninhibited just before 
the next aspirin intake.17 This is supported by a recent study, which showed that 
platelet aggregation was insufficiently inhibited 24 hours after morning aspirin 
intake in 25% of the patients with established cvd.18 because it is desirable to 
achieve optimal inhibition of platelet aggregation during the high risk morning 
hours, it might be beneficial to take aspirin at bedtime.19, 20 However, the effect of 
the timing of aspirin intake on the morning peak and circadian rhythm of platelet 
reactivity during 24 hours has not been investigated. Therefore, the aim of this 
study was to assess whether aspirin intake at bedtime compared with intake on 
awakening alters the circadian rhythm and reduces the morning peak of platelet 
reactivity in healthy subjects.
MeTHods
subjects
eligible participants were all healthy adults aged 18 or older, who had the capacity 
to give informed consent (ic). exclusion criteria were: active chronic disease, use of 
any other medication, allergy to salicylates, platelet count < 150*109/l, verifynow 
Aspirin reaction units (Aru) < 550, pregnancy, current smoking shift work <2 
months, history of major bleeding events, known bleeding diathesis, cardiovas-
56 chapter 4
cular disease, malignancy and extreme awakening- or bedtime hours, defined as 
regular (>2 days a week) bedtime <10 pM or >midnight and/or awakening <6 AM 
or >9 AM. participants were recruited through local advertisements in the leiden 
university Medical center (luMc, leiden, the netherlands).
design
This study was designed as a prospective randomized open-label blinded-end-point 
(probe) two-period crossover trial.21 A computer-generated randomization code 
was prepared by an independent person at the department of clinical epidemiol-
ogy of the luMc, which was inaccessible to the investigators to guarantee treat-
ment allocation concealment. The study was designed and reported in accordance 
with the consorT guidelines for randomized, controlled trials and registered 
at www.clinicaltrials.gov/ct2/show/ncT01900639. The study was approved by the 
luMc ethics committee and all participants gave written informed consent.
After a screening visit, participants were randomized into two groups. one group 
took aspirin on awakening during two weeks and subsequently at bedtime during 
two weeks, whereas the other group received the same interventions in opposite 
order. The intervention periods were separated by a washout period of 4 weeks. 
subjects were instructed to take 80 mg of effervescent acetylsalicylic acid (TevA 
pharmaceuticals, Amsterdam, the netherlands) in the morning between 7 and 
10 AM or in the evening between 10 pM and midnight, respectively. participants 
visited the research site at the beginning of each 2-week intervention period for 
instructions and new study medication for the subsequent period. At the end of 
both intervention periods, subjects were admitted for 24 hours to the research 
department after an overnight fast (Table 1). Thus, each subject was admitted 
twice for 24 hours, both after intervention with aspirin on awakening and after 
intervention with aspirin at bedtime.
All study medication was prepared by the pharmacy of the luMc. Medication 
compliance was registered and optimized with electronic pill boxes (evalan, Am-
sterdam, the netherlands), which sends a text message by phone when subjects 
do not open the box within the pre-specified time window. Additionally, a pill 
count was performed after both intervention periods. noncompliance was defined 
as an adherence of <90% as registered by the electronic pill box, as a remaining 
pill count of ≥3, or the subject’s acknowledgement of noncompliance. At each 
study visit, we registered possible adverse events and side effects of aspirin use by 
structured questionnaires.
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Twenty-four-hour Admission periods
After each intervention period, subjects were admitted from 8 AM to noon the next 
day. An overview of the schedule during admission is given in table 1. because the 
absorption of aspirin after intake could be affected by food intake, the timing of 
breakfast, lunch, and dinner, these variables were fixed for all subjects.22 subjects 
were allowed to sleep from midnight to 8 AM, during which the lights were turned 
off. After awakening, subjects were asked to ambulate for 15 minutes to resemble 
normal morning activity. during the rest of the day, subjects behaved according to 
their personal preference, but were not allowed to perform physical exercise.
using an 18 gauge antecubital venous catheter (vc) (becton dickinson inc., 
Franklin lakes, nJ, usA), blood was sampled every 3 hours. This sampling rate is 
analogous to a previous study on the circadian rhythm of platelet aggregation.23 
Additional samples were drawn at 9 AM and 11 pM, just before each supervised 
Table 1. day scheme of admission at visit 2 and 4
Time Action*
Day 1 8:30 insertion intravenous catheter
9:00 blood sampling








23:00 blood sampling (+sTxb2)
23:05 intake of aspirin when at bedtime
Day 2 00:00 blood sampling – lights off
03:00 blood sampling
6:00 blood sampling (+sTxb2 + Flow cytometry)
8:00 lights on - awakening
8:15 15 minutes ambulating
9:00 blood sampling (+sTxb2 + Flow cytometry)
9:05 intake of aspirin when taking it at awakening
9:30 breakfast
12:00 blood sampling (+sTxb2 + Flow cytometry)
* At every blood sampling moment a verifynow tube was drawn.
sTxb2: serum thromboxane b2. The grey area represents the morning peak of platelet reactivity 
at day 2.
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aspirin intake. each first 5 ml was discarded, after which blood for platelet func-
tion testing was drawn, followed by infusion of saline to keep the vc patent. Ad-
ditional tubes for determination of serum thromboxane b2 (sTxb2) were drawn at 
11 pM on day 1, and 6 AM, 9 AM and 12 AM on day 2.
laboratory measurements
At baseline and at the beginning of each 24-hour admission period, hematologic 
variables were determined according to standard procedures. platelet activity was 
evaluated with coX-1-dependent and coX-1-independent assays.
COX-1-dependent assays
platelet reactivity was measured with the verifynow Aspirin Assay (Accumetrics, 
san diego, cA, usA) as described previously.24 The verifynow Aspirin system con-
verts measured platelet aggregation into Aspirin reaction units (Aru). Higher Aru 
values correspond with higher platelet reactivity. Although manufacturer’s instruc-
tions allow measurement of platelet reactivity between 30 min – 4 hours after 
blood draw, we measured all samples 3 hours after each blood draw, to prevent 
time-dependent changes of platelet reactivity within the determination window.25 
sTxb2 is a stable metabolite of thromboxane A2 (TxA2), which directly reflects 
platelet coX-1 enzyme capacity, and is pharmacologically the most specific assay 
to evaluate the effect of aspirin on platelets.14, 26 Whole blood was allowed to clot 
at 37°c in non-anticoagulated tubes for 1 hour, after which serum was separated 
by centrifugation and stored at -80°c until analysis. sTxb2 was measured with an 
enzyme immuno-assay according to manufacturers’ instructions (Thromboxane b2 
express, cayman chemicals, Ann Arbor, Mi, usA).
COX-1-independent assays
For coX-1-independent assays, blood was drawn at 6 AM, 9 AM and 12 AM of day 
2. Four weeks after the last aspirin intake blood was drawn for controls. platelet 
reactivity was determined by agonist induced platelet surface cd62p (p-selectin) 
expression and platelet microaggregation. As agonists, thrombin receptor–activat-
ing peptide (TrAp; activates the thrombin receptor proteinase-activated receptors– 
1)27, adenosine diphosphate (Adp; activates p2y1, p2y12, and p2X1 receptors)28, 
phorbol 12-myristate 13-acetate (pMA; activates protein kinase c which in turn 
indirectly activates αiibβ3 integrin)29 and ristocetin (binds von Willebrand factor, 
changes its conformation and subsequently activates platelets through glyco-
protein ib binding) were used.30 induced platelet surface cd62p expression was 
determined as described previously.31 concentration series ranged from 625 µmol/l 
– 38 nmol/l (TrAp; H-2936, bachem, Weil am rhein, Germany), 125 µmol/l – 8 
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nmol/l (Adp; 01897, sigma-Aldrich, Zwijndrecht, the netherlands) and 8 µmol/l – 
0.5 nmol/l (pMA; p8139, sigma-Aldrich), platelet microaggregation was performed 
as described previously.30 in short, citrated blood was labelled with either FiTc 
Mouse Anti-Human cd31 (1:100; 555445; bd pharmingen™, san diego, cA, usA) 
or Alexa Fluor® 647 Mouse anti-Human cd31 (1:100; 558094, bd pharmingen™). 
The differently labeled platelets were mixed and subsequently activated with TrAp 
(250 µmol/l), Adp (50 µmol/l), pMA (160 nmol/l) or ristocetin (700 µmol/l; r7752, 
sigma-Aldrich). samples were taken at 0s, 30s, 60s, 120s, 180s, 300s and 480s, 
measured by flow cytometry (coulter Fc-500-Mpl, beckman coulter, Fullerton, cA, 
usA) and analyzed with Kaluza Analysis software (beckman coulter). cd62p ex-
pression was determined in the cd61 positive population. The cd62p-positive gate 
was established using unlabelled cells and isotype controls. The mean percentage 
of cd62p-positive in the eight concentrations was calculated. Microaggregation 
was quantified using a quadrant in the dot plot of non-stimulated samples. The 
percentage double positive samples were calculated relative to the total amount 
of positive events. platelet microaggregation increased over time and after 30 s for 
TrAp, Adp and ristocetin and after 180 s for pMA. The largest discrimination was 
observed and these values are reported in this manuscript.
statistical Analysis
To achieve a power of 90% with a 95% confidence level to find a reduction of 65 
Aru at the morning peak with aspirin intake at bedtime, 12 subjects were needed 
in this cross-over study32. For this calculation, we used an intra-individual standard 
deviation of 46.85 Aru, as extracted from a previous study33. 65 Aru corresponds 
with 1.5 times the intra-individual standard deviation, which we regarded as a pos-
sibly clinically relevant difference. Anticipating drop-out of approximately 10%, 
14 subjects were randomized. The primary analysis was guided by the intention 
to treat principle. second, a per-protocol analysis was performed in which partici-
pants were excluded who started smoking, started using other medication, or who 
did not take aspirin in the pre-specified time windows during the study. Third, a 
sensitivity analysis was performed, in which only measurements without the use of 
a tourniquet were analysed. Tourniquet use during blood draws results in higher 
intravascular pressure and can induce a turbulent blood flow which subsequently 
activates platelets and thereby influence the results.34 linear mixed models were 
used to compare platelet reactivity over the whole 24 hour (verifynow) and during 
morning hours on day 2 (6 AM – noon; all platelet activity measurements). Addition-
ally, the area under the curve (Auc) during morning hours on day 2 was calculated 
for each participant using the linear trapezoidal method, which uses the following 
equation: ∑(xn−xn−1)(yn+yn−1)/2. paired t-tests were used to test differences in Aucs. 
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spss statistics 20 (ibM corp., usA) and Graphpad prism 6 (Graphpad software inc., 
usA) were used for statistical calculations and graphical presentation of results.
resulTs
recruitment and study population
From June 2013 to october 2013, a total of 44 subjects were screened for eligibility, 
of whom 14 subjects refused to participate and 8 subjects did not meet the inclu-







































Assessed for eligibility (n=44) 
Excluded  (n=22) 
- Not meeting inclusion criteria (n=8) 
- Declined to participate (n=14) 
Not randomized because sufficient number 
participants reached (n= 8) 
Randomized (n=14) 
Allocated to Bedtime-Awakening  
(n=7) 
- Received allocated intervention (n=7) 
Lost to follow-up (n=0) 
- Discontinued intervention (n=0) 
Lost to follow-up (n=0) 
- Discontinued intervention (n=0) 
Sensitivity analysis 
- Five measurements excluded 
because of tourniquet blood draw 
Allocated to Awakening-Bedtime (n=7) 
- Received allocated intervention (n=7) 
Intention-to-treat population (n=7) 
Sensitivity analysis 
- All 153 measurements analysed 
 
Per protocol analysis (n=6) 
- Excluded: extreme chronotype (n=1) 
Per protocol analysis (n=6) 
- Excluded: compliance <90% (n=1) 





















Figure 1 – Flowchart of study patients.
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and 2 because of a known bleeding diathesis. Another 3 subjects were excluded 
because of extreme awakening- or bedtime hours, shift work in the preceding two 
months or current smoking. in addition, 8 subjects were meeting the inclusion 
criteria but were not randomized because sufficient number of participants had 
already been included. Finally, 14 subjects were randomized (Figure 1). baseline 
characteristics of the randomized subjects are listed in table 2. compliance, vali-
dated by electronic pill boxes, was high during the whole study, and similar with 
intake on awakening and at bedtime (96.5% and 97.2%, respectively).
coX-1-dependent platelet reactivity
The effect of intake of low-dose aspirin on awakening or at bedtime on the circa-
dian rhythm and morning peak of coX-1-dependent platelet assays are shown in 
figure 2. verifynow platelet reactivity reached its maximum at 6 AM with aspirin 
intake on awakening and shifted to noon with intake at bedtime. Mean verifynow 
platelet reactivity over the whole day was 438 (sd 54) Aru with intake on awaken-
ing and 430 (sd 59) Aru with intake at bedtime (mean difference: -9 [95% ci -21 
to 4]; p=0.190). Mean verifynow platelet reactivity during the morning peak was 
445 (sd 63) with intake on awakening, whereas this was 421 (sd 61) with aspirin 
intake at bedtime (mean difference -23 Aru [95% ci -50 to 4; p=0.09]). The mean 
verifynow Auc was higher during the morning peak with intake of aspirin on 
awakening (882 ± sd 107) than with intake at bedtime (851 ± sd 105), although this 
was not statistically significant (mean difference -31 [95% ci: -88 to 26] p=0.256). 
Aspirin intake at bedtime reduced sTxb2 mean and Auc during morning hours. 
Mean levels of sTxb2 during the morning peak with aspirin intake on awakening 
was 4.3 (sd 2.8) ng/ml with intake on awakening, whereas this was 2.6 (sd 1.3) ng/
ml with intake at bedtime (mean difference -1.7 [95% ci -2.7 to -0.8]; p=0.001). 
Table 2. baseline characteristics of 14 randomized subjects
characteristic Healthy Volunteers (n=14)
Age (years) 22.2 ± 1.8
sex (female) 9 (64.3)
body Mass index (kg/m2) 22.8 ± 2.7
Hemoglobin (mmol/l) males 9.3 ± 0.7
females 8.2 ± 0.7
platelet count (x109/l) 236 ± 33
Mean platelet volume (fl) 10.8 ± 1.1
platelet distribution width (µm) 13.2 ± 2.4
verifynow (Aspirin reaction units [Aru]) 642 ± 20
data are number (%) or mean ± sd
62 chapter 4







Circadian rhythm of VerifyNow-Aspirin Platelet reactivity
Without the use of a tourniquet
Aspirin intake on awakening (9:00h)
Aspirin intake at bedtime (23:00h) Morning peak
A





































Time-dependent effect of aspirin intake on Serum Thromboxane B2
Without the use of a tourniquet
Aspirin intake on awakening (9:00h)
Aspirin intake at bedtime (23:00h)
Day 2 (morning peak)Day 1
23:00 6:00 9:00 12:00
















: :  :  : : : :  :  :  :  
ir i  r t  f rif - iri  l t l t r ti it
ithout the use of a tourniquet
s iri  i t k   k i  ( : )
s iri  i t k  t ti  ( : ) r i  k




































i - t ff t f iri  i t   r  r  
it t t  s  f  t r i t
iri  i t   i  ( : )
iri  i t  t ti  ( : )
y  ( r i  k)y 
: : : :
















Figure 2 – effect of aspirin intake on awakening or at bedtime on circadian rhythm and morn-
ing hour coX-1-dependent platelet activity. panel A) verifynow-Aspirin platelet reactivity. Grey 
shaded area depicts the morning peak of platelet reactivity and cardiovascular events. panel 
B) serum Thromboxane b2. Figures are the results of the sensitivity analysis, in which measure-
ments after tourniquet blood draw (n=5 (1.6%)) were excluded. values are depicted as means 
± standard error.
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Aspirin intake on awakening (9:00h)

























































































































ADP (p-selectin) PMA (p-selectin)
TRAP (FCA) Ristocetin (FCA)
ADP (FCA) PMA (FCA)
G
Figure 3 – effect of aspirin intake on awakening or at bedtime on coX-1-independent platelet 
assays during morning hours. panel A to c) Flow cytomety cd62 (p-selectin) surface expression 
after activation with respectively Thrombin receptor agonist peptide (TrAp), adenosine diphos-
phate (Adp) and phorbol 12-myristate 13-acetate (pMA). panel D to F) Flow cytometry based 
aggregation (FcA) after activation with respectively TrAp, ristocetin, Adp and pMA.
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The mean Auc of sTxb2 levels during the morning peak was also lower with aspirin 
intake at bedtime (mean difference -4.7 [95% ci -6.9 to -2.5]).
Two subjects were excluded in the per-protocol analysis, because of compliance 
<90% and change of chronotype during the study. The results of the per protocol 
analysis for verifynow platelet reactivity and sTxb2 were similar to the intention 
to treat analysis (Appendix table). in our sensitivity analysis, which excluded 
tourniquet blood draws (5/304; 1.6%), aspirin intake at bedtime reduced morning 
verifynow platelet reactivity with 30 Aru (95% ci -56 to -3; p=0.03) compared with 
on awakening. Additionally, the mean difference in Auc during the morning peak 
was larger (-52 [95% ci: -105 to 2]; p=0.057) in this sensitivity analysis.
coX-1-independent platelet reactivity
The mean percentage platelet surface p-selectin expression during morning hours 
after activation with respectively TrAp, Adp and pMA was 55.5 (sd 6.0), 15.2 (sd 
6.3) and 22.5 (sd 4.9) after aspirin intake on awakening and 56.0 (sd 6.6), 16.0 (sd 
8.1) and 22.1 (sd 7.7) after aspirin intake at bedtime (Figure 3; Appendix table). in 
the per-protocol- and sensitivity analysis results were similar as the intention-to-
treat analysis (Appendix table). so, the mean cd62p expression after stimulation 
with TrAp, Adp and pMA was not affected by the time of aspirin intake. spontane-
ous and maximum platelet microaggregation did not differ between aspirin intake 
upon awakening or at bedtime (data not shown). The mean percentage of double 
positive events during morning hours after stimulation with TrAp, Adp, pMA and 
ristocetin was 25.1 (sd 3.6), 23.5 (sd 4.7), 9.6 (sd 5.0) and 22.5 (sd 4.9) after aspirin 
intake on awakening and 26.6 (sd 3.9), 25.4 (sd 3.8), 10.4 (sd 4.7) and 22.7 (sd 4.1) 
after aspirin intake at bedtime, respectively. similar results were obtained in the 
per protocol and sensitivity analysis (Appendix table). notably, both the platelet 
responsiveness- and microaggregation assay were not affected by aspirin intake at 
all, irrespective of time of intake (Figure 3).
discussion
The main finding of this study is that aspirin intake at bedtime compared with 
intake on awakening reduces coX-1-dependent platelet reactivity during the 
morning hours. Furthermore, aspirin intake at bedtime appeared to shift the peak 
of platelet reactivity away from the morning hours.
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comparison with previous studies
previous authors suggested that the morning peak of platelet reactivity could be 
reduced by taking aspirin at bedtime instead of on awakening.19, 20, 35 However, 
to our knowledge, this has never been evaluated in a clinical trial. The physicians 
Health study showed that the protective effect of aspirin was most pronounced 
for morning myocardial infarctions, although the time of aspirin intake was not 
reported.36 in the only study which specifically assessed the effect of aspirin intake 
on morning platelet reactivity, aspirin was taken at 9 pM.37 in this study, aspirin 
intake at 9 pM compared with placebo abolished the morning peak of platelet 
aggregation, which is in line with our study. However, only one dose of 325 mg 
enteric coated aspirin was administered and no direct comparison with morning 
intake was made in that study. in our study, 80 mg of plain effervescent aspirin was 
taken for 14 consecutive days and the effect of intake on awakening and bedtime 
was directly compared. it is known that stable platelet inhibition by low-dose 
aspirin (80-100 mg) can take several days.14 Furthermore, recent clinical guidelines 
recommend a daily dose of 50 to 160 mg for cvd prevention.38 Thus, our study 
most closely represents current clinical practice with respect to chronic daily use of 
low-dose aspirin for cvd prevention.
We found time-dependent differences with coX-1-dependent-, but not with 
coX-1-independent platelet reactivity measurements. This can be explained by 
aspirin not affecting these coX-1-independent pathways, as indicated by our 
results in which coX-1-independent platelet activity was not affected by aspirin 
in general.
strengths and limitations
The major strength of this study is that we used a cross-over design, which elimi-
nated between-person variability and determinants of platelet reactivity.39 We se-
lected individuals with a pre-specified non-extreme chronotype, which optimized 
homogeneity of circadian biological rhythms between study participants. Further-
more, compliance during the intervention periods was optimally controlled with 
the combined use of electronic pill boxes and pill counts. only 2 subjects were less 
than 90% compliant or changed their chronotype during the study, which did not 
materially affect our results as confirmed by the results of a per protocol analysis.
platelet reactivity during morning hours is affected by physical activity.40 There-
fore, a limitation of our study is that participants were not admitted on the day 
before the start of our measurements to standardize behaviour and physical activ-
ity in the first measurement hours. This limitation is reflected by the difference in 
verifynow platelet reactivity during the morning hours on measurement day 1 and 
2 (Figure 2). This could be explained by differences in physical activity necessary to 
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reach the study site that might have activated platelets. behaviour and physical 
activity during admission were standardized, and therefore more reliable to assess 
treatment effects during the morning peak on day 2. Another limitation is that 
we only used the verifynow-Aspirin device to measure aspirin-related platelet 
reactivity, while several other devices are available. Although light transmission 
aggregometry (lTA) is the historical golden standard, lTA is more time consuming 
than the point-of-care verifynow, requires specialized laboratory technicians and 
additional blood manipulation. of all alternatives, verifynow shows the strongest 
correlation with lTA.41 in addition, we measured serum levels of Txb2, which is 
pharmacologically the most specific test for aspirins’ effect on platelets.26
Finally, our study was conducted in healthy individuals and not in cvd patients. 
yet, patients with cvd have higher platelet turnover, which would result in a 
higher proportion of uninhibited platelets 24 hours after aspirin intake. Therefore, 
we expect that the observed effects will be even larger in cvd patients.15 This is 
supported by a recent study, in which higher platelet turnover was associated with 
insufficient platelet inhibition 24 hours after morning aspirin intake in 25% of cvd 
patients.18
clinical implications
The morning peak of platelet reactivity is likely to contribute to the morning peak 
of acute cardiovascular events.5 However, despite antiplatelet therapy, a morning 
peak is still present in patients with recurrent events.7 Aspirin intake at bedtime 
instead of on awakening might attenuate this morning peak by optimizing platelet 
inhibition during these high risk morning hours. because acute arterial thrombosis 
is a multifactorial process and coX-1 only affects a part of total platelet reactiv-
ity , we do not expect that more efficient coX-1-dependent platelet inhibition 
abolishes the morning peak of cardiovascular events completely.42 For example, in 
a previous study in aspirin treated patients, poor clinical outcomes correlated with 
both high values of coX-1-dependent (sTxb2) and coX-1-independent assays.
43 The 
expected benefit of specifically reducing coX-1-dependent platelet reactivity could 
also be derived from previous studies, in which the risk of recurrent cardiovascular 
events was increased in patients with higher verifynow-Aspirin platelet reactiv-
ity.44, 45 stable cvd patients with platelet reactivity >550 Aru had an absolute risk 
of 15.6% for developing the composite cardiovascular endpoint, whereas this was 
only 5.3% in patients with Aru values <550.45 in another study, the absolute risk 
for the primary endpoint (all-cause death and recurrent cardiovascular events) was 
13.3% in patients >454 Aru and 5.9% in patients <454 Aru.44 Although these 
observational studies suggest that already a modest reduction in coX-1- depen-
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dent platelet reactivity could result in clinical benefit, future clinical trials should 
evaluate whether this indeed leads to a reduction of cardiovascular events.
conclusion
This study suggests that low-dose aspirin taken at bedtime compared with intake 
on awakening reduces coX-1-dependent platelet reactivity during morning hours 
in healthy subjects. Future clinical trials in larger patient groups are required to 
investigate whether simply switching to aspirin intake at bedtime reduces the risk 
of cardiovascular events during the morning hours.
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cardiovascular disease is one of the leading causes of morbidity and mortality 
worldwide. in spite of improvements in secondary prevention over the last de-
cades 20-40% of patients develop a recurrent event.1 platelets are key players in 
the development of arterial thrombosis. consequently, a cornerstone of second-
ary prevention comprises the inhibition of platelets.2, 3 Following international 
guidelines, classical risk factors are aggressively treated after a first cardiovascular 
event. yet, other biological mechanisms may play a role in developing a recur-
rent event. platelet characteristics, such as increased basal reactivity, has been 
proposed to be one of those mechanisms. At the occurrence of arterial thrombosis, 
platelets are activated and release granule contents into the vasculature, including 
chemokines which interact with other blood cells and the endothelium.4, 5 Three 
of these chemokines are nAp-2 (neutrophil-activating peptide-2), which is an 
activation product of cXcl7 (cXc chemokine ligand 7, also known as precursor of 
beta-thromboglobulin), cXcl4 (cXc chemokine ligand 4 ,also known as platelet 
factor 4) and rAnTes (regulated on activation, normal T cell expressed and se-
creted), which modulates monocytes involved in the progression of atherosclerotic 
plaques.6 We measured nAp-2, cXcl-4 and rAnTes because these markers were 
studied previously in relation to cardiovascular disease and serve as a marker of 
basal platelet activity.6-17 We hypothesized that increased basal activity of these 
platelet markers increase the risk of a recurrent cardiovascular event. in the pres-
ent study we studied the association between plasma concentrations of nAp-2, 
cXcl4 and rAnTes and the incidence of recurrent cardiovascular events in men 
with a history of myocardial infarction.
A cohort study was performed among men who experienced a first myocardial 
infarction (Mi) between 1990 and 1996. details of the study have been reported 
previously.18 in short, patients were followed until september 1st 2004 to asses the oc-
currence of recurrent major arterial cardiovascular events (rMAce). Follow-up infor-
mation was collected from hospital files, general practioners and patient question-
naires. The study was approved by the local ethics committee and all patients gave 
written informed consent. A blood sample was collected from each patient after the 
first event to determine levels of platelet markers (nAp-2, cXcl4 and rAnTes) using 
semi-automated elisA as described previously.12, 19 High levels of platelet reactivity 
were defined as levels above the 90th percentile. continuous data are summarized as 
medians with interquartile range (iQr) and categorical data are presented as counts 
and percentages. cox proportional hazard models were used to estimate hazard 
ratios for the occurrence of rMAce according to different concentrations of the 
platelet markers. Hazard ratios were adjusted for putative confounding factors in 
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the relation between the platelet reactivity markers and rMAce. sensitivity analyses 
using continuous variables and different cut-off points were performed.
A total of 542 men were included in the cohort who experienced a first myocar-
dial infarction at a median age of 57 years (iQr 49-64), and for whom median 
follow-up time was 9.2 years (iQr 2.7 – 11.4). during follow-up, 254 (47%) men 
developed at least one rMAce. Median time between first Mi and blood sampling 
was 2.6yrs (range 0.2 – 6yrs), which did not differ between the patients with rMAce 
and no rMAce. platelet reactivity markers were missing in 41 patients, of whom 
clinical characteristics did not differ from the non-missing patients. For all platelet 
reactivity markers, patients with a level above the 90th percentile did not have 
an increased risk of developing an rMAce compared with patients with platelet 
reactivity markers below the 90th percentile. Adjustment for potential confounders 
did not change (cXcl4 and rAnTes) or attenuated (nAp-2) the risk estimates even 
further (table). changing the cut-off points or using platelet reactivity as continu-
ous variable did not affect the results.
our findings in a cohort of men who survived a first myocardial infarction do not 
confirm the notion that increased basal platelet reactivity increases the risk of 
recurrent cardiovascular events. This important negative finding contradicts previ-
ous studies which suggested that these inflammatory markers play a role in the 
development of first and recurrent cardiovascular events.12-17 regarding the beta-
thromboglobulin nAp-2, our findings are in line with the recent study of berent et 
al., in which no difference in recurrence of cardiovascular events was found between 
patients with low and high beta-thromboglobulin levels.20 A possible explanation 
for the absence of an association between platelet reactivity markers and recurrent 
cardiovascular events in our study is that our study population represented a group 
of stable patients with chronic cardiovascular disease, whereas patients in previous 
studies were studied in an acute setting.13-17 However, platelet inflammatory mark-
ers might play a more dominant role in the development of cardiovascular events 
in stable patients with a low prevalence of classical risk factors.12 A major strength 
of our study is the large sample size and long follow-up, since platelet inflam-
matory markers may affect the vascular endothelium over a long period of time 
before a recurrent cardiovascular event takes place. Additionally, our results can 
be generalized to other men with a first myocardial infarction, because our cohort 
was representative of a typical population of men who survived a first myocardial 
infarction. A limitation of our study is that renal function, which affects the level 
of beta-thromboglobulin21, was not measured and could not be controlled for as 
a confounding factor. However, because renal function and beta-thromboglobulin 
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are inversely correlated, additionally controlling for the effect of renal function 
would only attenuate the hazard ratios. unfortunately, due to practical reasons, 
we did not measure soluble glycoprotein ib (sGpib) in the current study, while a 
previous study in premenopausal women found an association between high levels 
of sGpib and myocardial infarction.12
in conclusion, we found that high platelet reactivity, as measured by cXcl4, nAp-
2 and rAnTes, does not increase the risk of recurrent cardiovascular events in men 
who survived a first myocardial infarction.
Table Hazard ratios for recurrent MAce (rMAce) in men with a first myocardial infarction ac-
cording to platelet reactivity markers
no rMAce 
(n=263)
rMAce (n=238) Hazard ratio (95% ci)
unadjusted Fully Adjusted*
nAp-2
< 90th percentile 240 211 1 [ref] 1 [ref]
≥ 90th percentile 23 27 1.3 (0.9-1.9) 1.1 (0.8-1.7)
cXcl4
< 90th percentile 239 212 1 [ref] 1 [ref]
≥ 90th percentile 24 26 1.2 (0.8-1.8) 1.2 (0.8-1.8)
rAnTes
< 90th percentile 239 212 1 [ref] 1 [ref]
≥ 90th percentile 24 26 1.2 (0.8-1.8) 1.2 (0.8-1.8)
nap-2: neutrophil activating peptide 2; cXcl4: cXc chemokine ligand 4; rAnTes: regulated on 
activation, normal T cell expressed and secreted.
* Adjusted for (at time of blood drawing): age, total cholesterol, systolic blood pressure, current 
smoking, c reactive protein and use of aspirin, oral anticoagulants, glucose lowering drugs, 
cholesterol lowering drugs.
AcKnoWledGMenTs
The authors thank the contributors to earlier phases of the study of Myocardial 
infarction leiden: cJM doggen, Md van der Krabben and the cardiologists of the 
departments of cardiology, leiden university Medical center and Hospital diacon-
essenhuis leiden, the netherlands. The original study, on which the present article 
is based, was supported by the netherlands Heart Foundation (grant 92.345). We 
also thank p.G. de Groot and A.d. barendrecht of the department of clinical chem-
istry and Haematology, university Medical center utrecht, the netherlands, who 
provided the measurements of platelet reactivity markers for this study.
78 chapter 5
reFerences
 1. roger vl, Go As, lloyd-Jones dM, Adams rJ, berry Jd, brown TM et al. Heart disease 
and stroke statistics 2011 update. Circulation 2011; 4: e18-e209.
 2. vandvik po, lincoff AM, Gore JM, Gutterman dd, sonnenberg FA, Alonso-coello p et 
al. primary and secondary prevention of cardiovascular disease. Chest 2012; 2 suppl: 
e637s-e668s.
 3. smith sc, Allen J, blair sn, bonow ro, brass lM, Fonarow Gc et al. AHA/Acc Guidelines 
for secondary prevention for patients With coronary and other Atherosclerotic vascu-
lar disease: 2006 update. Circulation 2006; 19: 2363-72.
 4. von Hundelshausen p, Weber c. platelets as immune cells: bridging inflammation and 
cardiovascular disease. Circ Res 2007; 1: 27-40.
 5. Weber c. platelets and chemokines in atherosclerosis: partners in crime. Circ Res 2005; 
6: 612-6.
 6. von Hundelshausen p, Weber Ksc, Huo y, proudfoot Aei, nelson pJ, ley K et al. rAnTes 
deposition by platelets Triggers Monocyte Arrest on inflamed and Atherosclerotic 
endothelium. Circulation 2001; 13: 1772-7.
 7. deuel TF, senior rM, chang d, Griffin Gl, Heinrikson rl, Kaiser eT. platelet factor 4 is 
chemotactic for neutrophils and monocytes. Proc Natl Acad Sci U S A 1981; 7: 4584-7.
 8. lane dA, ireland H, Wolff s, ranasinghe e, dawes J. detection of enhanced in vivo 
platelet alpha-granule release in different patient groups - comparison of beta-throm-
boglobulin, platelet factor 4 and thrombospondin assays. Thromb Haemost 1984; 2: 
183-7.
 9. nassar T, sachais bs, Akkawi s, Kowalska MA, bdeir K, leitersdorf e et al. platelet factor 
4 enhances the binding of oxidized low-density lipoprotein to vascular wall cells. J Biol 
Chem 2003; 8: 6187-93.
 10. preston rJ, Tran s, Johnson JA, ni AF, Harmon s, White b et al. platelet factor 4 impairs 
the anticoagulant activity of activated protein c. J Biol Chem 2009; 9: 5869-75.
 11. sachais bs, Kuo A, nassar T, Morgan J, Kariko K, Williams KJ et al. platelet factor 4 binds 
to low-density lipoprotein receptors and disrupts the endocytic machinery, resulting in 
retention of low-density lipoprotein on the cell surface. Blood 2002; 10: 3613-22.
 12. snoep Jd, roest M, barendrecht Ad, de Groot pG, rosendaal Fr, van der bom JG. High 
platelet reactivity is associated with myocardial infarction in premenopausal women: 
a population-based case-control study. J Thromb Haemost 2010; 5: 906-13.
 13. cavusoglu e, eng c, chopra v, clark lT, pinsky dJ, Marmur Jd. low plasma rAnTes lev-
els are an independent predictor of cardiac mortality in patients referred for coronary 
angiography. Arterioscler Thromb Vasc Biol 2007; 4: 929-35.
 14. smith c, damas J, otterdal K, oie e, sandberg WJ, yndestad A et al. increased levels 
of neutrophil-Activating peptide-2 in Acute coronary syndromes: possible role of 
platelet-Mediated vascular inflammation. Journal of the American College of Cardiol-
ogy 2006; 8: 1591-9.
 15. sobel M, salzman eW, davies Gc, Handin ri, sweeney J, ploetz J et al. circulating 
platelet products in unstable angina pectoris. Circulation 1981; 2: 300-6.
 16. Taomoto K, Asada M, Kanazawa y, Matsumoto s. usefulness of the measurement of 
plasma beta-thromboglobulin (beta-TG) in cerebrovascular disease. Stroke 1983; 4: 518-
24.
platelet reactivity and recurrent vascular events 79
 17. rasi v, ikkala e, Torstila i. plasma thromboglobulin in acute myocardial infarction. 
Thrombosis Research 1982; 3: 203-12.
 18. van der Krabben, rosendaal Fr, van der bom JG, doggen cJM. polymorphisms in 
coagulation factors and the risk of recurrent cardiovascular events in men after a first 
myocardial infarction. Journal of Thrombosis and Haemostasis 2008; 5: 720-5.
 19. van bladel er, roest M, de Groot pG, schutgens re. up-regulation of platelet activa-
tion in hemophilia A. Haematologica 2011; 6: 888-95.
 20. berent r, Auer J, Franklin b, schmid p, von duvillard sp. platelet response to Aspirin 
50 and 100 mg in patients With coronary Heart disease over a Five-year period. The 
American Journal of Cardiology .
 21. Andrassy K, deppermann d, ritz e, Koderisch J, seelig H. different effects of renal 
failure on beta-thromboglobulin and high affinity platelet factor 4 (HA-pF4)-concen-
trations. Thromb Res 1980; 3-4: 469-75.

chapter 6
effect of beta-blockers 
on platelet aggregation: 
a systematic review 
and meta-analysis
T.n. bonten, c.e.i. plaizier, J.d. snoep, T. stijnen, o.M. dekkers, 
J.G. van der bom




platelets play an important role in cardiovascular disease (cvd) and beta-blockers 
are often prescribed for cvd prevention. beta-blockers may directly affect platelet 
aggregation, because beta-adrenergic receptors are present on platelets. There is 
uncertainty about the existence and magnitude of an effect of beta-blockers on 
platelet aggregation.
Methods and results
We performed a systematic review and meta-analysis on the effect of beta-blockers 
on platelet aggregation. We retrieved 31 studies (28 clinical trials, 3 observational 
studies). beta-blockers decreased platelet aggregation: standardized mean differ-
ence -0.54 (95% ci -0.85 to -0.24, p<0.0001). This corresponds to a reduction of 
13% (95% ci 8 to 17%). non-selective lipophilic beta-blockers decreased platelet 
aggregation more than selective non-lipophilic beta-blockers.
conclusion
clinically used beta-blockers significantly reduce platelet aggregation. non-selec-
tive lipophilic beta-blockers seem to reduce platelet aggregation more effectively 
than selective non-lipophilic beta-blockers. These findings may help to explain why 
some beta-blockers are more effective than others in preventing cvd.
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inTroducTion
cardiovascular disease (cvd) is a major cause of mortality and morbidity world-
wide.1,2 Anti-platelet and beta-blocking drugs are cornerstones in the secondary 
prevention of cvd.3-6 The aim of anti-platelet therapy is to inhibit prothrombotic 
and anti-inflammatory platelet properties, which contribute to the pathogenesis 
of cvd7. beta-blockers are recommended for secondary prevention of cvd because 
of their beneficial effects on heart rate, blood pressure and myocardial oxygen de-
mand.5,6,8 yet, beta-blocking agents may also affect platelet aggregation, because 
beta-adrenergic receptors are present on platelets and catecholamine levels are 
known to potentiate platelet reactivity.9 The beta-adrenergic receptor on human 
platelets is mainly from the beta-2-subtype, which is only inhibited by non-selective 
beta-blockers.10 This suggest that non-selective beta-blockers would have a more 
pronounced effect on platelet aggregation than selective beta-blockers.11 besides, 
beta-blockers have a membrane stabilizing effect which, depending on the lipo-
philicity of the compounds, could also affect platelet aggregation.10,12
Although beta-blockers are one of the most frequently prescribed drugs for cvd 
prevention and notwithstanding the mechanistic plausibility, there is still uncer-
tainty about the existence and magnitude of an effect of beta-blockers on platelet 
aggregation.13 our aim was to synthesize the currently available evidence on the 
effect of beta-blockers on platelet aggregation and to examine whether this effect 
is modulated by the selectivity and lipophilicity of the beta-blockers.
MeTHods
search strategy
Medline and eMbAse were searched until June 2013. The search terms used were 
“platelet Aggregation” and “beta blockers” or “Adrenergic beta-antagonists” 
(an overview of the complete search string is shown in Appendix methods 1). The 
search was extended by review of bibliographies from articles included in the final 
selection.
eligibility criteria
eligible articles had to report on the effect of beta-blockers on platelet aggregation 
measured by light Transmission Aggregometry (lTA). in vitro studies, defined as 
studies in which beta-blockers were added after blood drawing, were not eligible. 
non-english articles, animal studies and platelet aggregation studies performed 
under conditions affecting platelet aggregation, i.e. physical or psychological 
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stress, acute cardiovascular disease or pregnancy, were not included. unpublished 
trials and data presented in short reports, conference abstracts or letters to the 
editor were also not eligible. only studies on beta-blockers WHo-registered for 
clinical use were considered (http://www.whocc.no/atc_ddd_index). studies were 
excluded if platelet aggregation was induced by an infrequently studied agonist, 
defined as an agonist that was used in one eligible study only.
risk of bias assessment
We assessed the risk of bias of the included studies according to the cochrane 
collaboration’s tool for assessing risk of bias.36 For the assessment of cross-over 
studies we added the characteristics ‘reported on carry-over effects’ and ‘pres-
ence of carry-over effects’ to the domain ‘other bias’. For observational studies, 
we added the characteristics ‘reporting in- and exclusion criteria’ and ‘Adequate 
control for confounding factors’ to the domain ‘other bias’. in accordance with the 
tool’s instruction, all dimensions were scored as ‘low risk of bias’ ‘high risk of bias’ 
or ‘unclear risk of bias’ by two independent reviewers (Tnb and ceip). disagree-
ment occurred in 5/264 (2%) scorings and was resolved by consensus.
To estimate the impact of studies with a high risk of bias, we performed a sensi-
tivity analysis by restricting the analysis to randomized studies, assuming a lower 
risk of bias for randomized studies. We regarded the domains on blinding as less 
important in the risk of bias assessment, because platelet aggregation is measured 
quantitatively. publication bias was examined using a funnel plot. To estimate 
the impact of possible publication bias, we performed a cumulative meta-analysis 
based on study precision (standard error).
data extraction
Two reviewers (Tnb and ceip) independently extracted data using standardized 
coding forms. For one-group (single treatment arm, no placebo) and cross-over 
(multiple treatment arms, interventions and placebo in each arm) trials we ex-
tracted data on platelet aggregation before and after intervention. For two-group 
trials (multiple treatment arms, intervention or placebo in each arm) we extracted 
data before and after intervention in the intervention and placebo groups. one 
two-group trial reported only data after intervention for the two trial arms, in 
which case we used that data for meta-analysis.37 of cross-sectional studies, we 
compared data on platelet aggregation between exposed and non-exposed 
groups. if results were presented in figures only, we extracted outcome measures 
from the appropriate figures where possible.38 When multiple measurements of 
platelet aggregation were performed in time, the last measurement was selected 
for analysis.
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effect size calculation and statistical procedures
because the measurement scale of platelet aggregation varied across studies, we 
calculated standardized mean differences (sMds) for each study. As four types of 
study designs were included (cross-sectional, one-group-, two-group- and cross-
over trials), we calculated sMds using the appropriate formulas for each design 
(Appendix methods 2).36,39-41 in brief, an sMd was calculated by dividing the mean 
difference by the pre-test standard deviation (sd) or sd of the non-exposed group 
for cross-sectional studies. sMd values were negative when the intervention (beta-
blocker) reduced the outcome (platelet aggregation), with effect sizes of -0.20, 
-0.50 and -0.80 representing small, medium and large reductions respectively.42 To 
facilitate interpretation, we additionally recalculated the overall effect size back to 
percentage platelet aggregation, a commonly used measurement scale in platelet 
aggregation studies, by multiplying the overall sMd with the mean sd (and 95% 
ci) of the studies which used percentage platelet aggregation as measurement 
scale. Most studies used multiple agonists to measure platelet aggregation. First, 
we analysed the effect of all agonists separately. second, we calculated the mean 
of the effect sizes for each study, so that each study contributed with only one 
effect size to the analysis.
A random-effects meta-analysis was performed by default, because of expected 
between-study heterogeneity.43 subgroup analyses were performed for studies 
with non-selective versus selective beta-blockers, non-lipophilic versus lipophilic 
beta-blockers, short- (intake < 1 week) versus long-term (intake > 1 week) expo-
sure and healthy versus diseased study population. if exposure duration was not 
reported, we assumed long-term exposure.44-46 univariate meta-regression analysis 
was performed for each subgroup. All analyses were performed with sTATA 12 
(statacorp lp, usA).
resulTs
literature search and study characteristics
A total of 1065 articles were identified through the literature search, of which 70 
were reviewed in detail. no additional publications were identified by review of 
bibliographies. A total of 31 studies, reported in 25 articles, were included (Figure 
1). We included 13 cross-over trials, 8 one-group trials, 7 two-group trials and 3 
cross-sectional studies in which a total of 454 subjects (range 4-43) were studied 
(details of included studies are shown in Appendix table 1). The majority of the 
studies (n=25) included patients with cardiovascular disease or cardiovascular 
disease risk factors (hypertension, coronary artery disease, diabetes or previous 
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myocardial infarction). Mean age ranged from 33 to 74.5 years. Most studies (n=26) 
reported on long-term exposure (>1 week) and non-selective beta-blockers such as 
carvedilol, propranolol, labetalol or timolol (n=23).




1065 articles identified through database searches 
70 articles retrieved for detailed review 
25 articles included, containing 31 studies for 
meta-analysis 
388 duplicate or non-English excluded 
 156 Duplicates 
 232 Non-English full text 
607 excluded by review of title and 
abstract 
409 No β-blocker or platelet     
aggregation studied 
121 Animal studies 
28  Platelet aggregation studies 
performed under conditions 
affecting platelet aggregation* 
25  In vitro studies† 
24  Editorials, short reports 
 
45 excluded by review of full-text article 
 
22  No adequate data‡ 
14  Infrequently used platelet 
aggregation method  
7  β-blocker not used in current 
medical practice 
2  Infrequently used agonist of 
platelet aggregation  
Figure 1 – Flow chart of study selection
* conditions affecting platelet aggregation: physical or psychological stress, acute cardiovascu-
lar disease or pregnancy.
† in vitro was defined as studies in which beta-blockers were added after blood drawing.
‡ no outcome measures and/or no measure of variability (se or sd), t-statistic or exact p-value 
reported.
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Meta-analysis of effect of beta-blockers on platelet aggregation
The 31 included studies contained a total of 81 observations on platelet aggre-
gation. The most used agonist to induce platelet aggregation was adenosine 
diphosphate (Adp) (52%), followed by collagen (20%) and epinephrine (20%), 
whereas Arachidonic acid (n=5) and Thrombin (n=2) were used in the minority 
of experiments. The effect of beta-blockers on platelet aggregation was maximal 
with the use of epinephrine as an antagonist (Figure 2).
When study observations and antagonists were pooled, 13% (n=4) of the studies 
showed an increase in platelet aggregation, whereas the majority (84%; n=26) 
showed a decrease in platelet aggregation due to beta-blockers. random effects 
meta-analysis showed a decrease in platelet aggregation with exposure to beta-
blockers: sMd -0.54 (95% ci -0.85 to -0.24, p<0.0001; Figure 3). This corresponds 
to a reduction of 13% (95% ci 8-17%) in platelet aggregation. subgroup analysis 
showed that non-selective and lipophilic beta-blockers (sMd -0.78 [95% ci -1.21 to 
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Figure 2 – effect of beta-blockers on platelet aggregation by agonists
Forest plot of standardized mean differences (sMd) of the effects of beta-blockers on platelet 
aggregation by different agonists. Adp: adenosine diphosphate.
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-0.27]) decreased platelet aggregation more than selective and non-lipophilic 
beta-blockers (sMd -0.14 [95% ci -0.40 to 0.12] and -0.21 [95% ci -0.51 to 0.08]; 
Figure 4). These differences were not statistically significant with meta-regression 
analysis (non-selective vs. selective: p=0.18; non-lipophilic vs. lipophilic: p=0.47). 
The effect was not different for studies with short- or long-term exposure and in 
healthy or non-healthy populations (p=0.94 and p=0.77; Figure 4).
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Figure 3 – overall effect over beta-blockers on platelet aggregation
Forest plot of standardized mean differences (sMd) of the effects of beta-blockers on platelet 
aggregation. The black diamonds represent the effect estimate (sMd), where a negative sMd 
represents a decrease of platelet aggregation. The size of the grey squares around the effect 
estimates corresponds to the weight of the study in the meta-analysis. Horizontal lines repre-
sent corresponding 95% confidence intervals (ci). The estimate and ci of the pooled effect is 
indicated by the diamond.
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risk of bias assessment and publication bias
A summary of the risk of bias assessment for clinical trials and observational studies 
is shown in Appendix figure 1. blinding was performed in 21/28 (75%) trials, but 
only 17/28 (61%) were double- or triple blinded. of cross-over trials, only 6/13 (46%) 
reported on carry-over effects. only 20/28 (71%) of all trials were randomized and 
only one trial described the randomisation procedure. in a sensitivity analysis with 
restriction to randomized trials only (n=20), the pooled effect estimate was sMd 
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Figure 4 – subgroup analyses
Forest plot of standardized mean differences (sMd) of the effects of subgroups beta-blockers 
on platelet aggregation. The effect estimates and ci of each subgroup are indicated by the 
diamonds. *subgroups: selective (metoprolol, atenolol), non-selective (propranolol, labetalol, 
timolol, carvedilol), lipophilic (propranolol, labetalol, timolol, metoprolol, carvedilol), non-
lipophilic (atenolol), Healthy subjects, diseased (hypertension, coronary artery disease, diabetes 
or previous myocardial infarction), short-term treatment (<1 week), long-term treatment (>1 
week).
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The funnel plot showed a relative lack of small studies with negative results 
(Figure 5). Two studies showed extreme effects, although their contributions to 
the overall effect were marginal (weights of 1.2% and 0.3%).14,15 exclusion of these 
two studies from our analysis did not materially affect the pooled effect estimate 
(sMd after exclusion: -0.41 [95% ci -0.65 to -0.17]). To estimate the impact of pos-
sible publication bias, we conducted a cumulative meta-analysis based on study 
precision (Appendix figure 2). This indicated that the overall effect estimate was 
influenced by small studies. However the effect estimate of the largest studies with 
the smallest standard errors was robust around sMd -0.25 to -0.30, again indicating 
a decrease in platelet aggregation with exposure to beta-blockers.
discussion
beta-blockers are one of the most frequently used drugs in prevention of cvd 
and platelets play an important role in the pathogenesis of cvd. until now it was 
unclear whether beta-blockers affected platelet aggregation. This meta-analysis 
demonstrates that clinically used doses of beta-blockers significantly reduce plate-
let aggregation. Additionally, it indicates that non-selective lipophilic beta-blockers 
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Figure 5 – Funnel plot
Funnel plot of all included studies. Two studies with extreme effects are the studies of campbell 
(1981; sMd -8) and Frishman (1978; sMd -6.5)
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previous studies
recent meta-analyses found that beta-blockers, as a class, effectively reduce 
cardiac- and all-cause mortality in patients with systolic heart failure and acute 
myocardial infarction.16,17 it is known that this is the result of beneficial effects 
on heart rate, blood pressure and myocardial oxygen demand.5,6,8 besides these 
established beneficial effects, the present meta-analysis suggests that part of the 
protective effect of beta-blockers could be the result of platelet aggregation inhibi-
tion. interestingly, recent meta-analyses found that the non-selective beta-blocker 
carvedilol was superior to selective beta-blockers, which is in line with the results 
and subgroup analysis of the coMeT trial.18,19 in these studies it was suggested that 
the non-selective lipophilic beta-blocker carvedilol exerts an additional beneficial 
effect through improvement of endothelial function, stimulating β-arresting sig-
nalling and anti-oxidant properties.20-22 our findings suggest that lipophilic non-
selective beta-blockers decrease platelet aggregation most effectively, which could 
in part explain the superiority of non-selective lipophilic beta-blockers.
Mechanisms of platelet aggregation reduction by beta-blockers
The inhibition of platelet aggregation by beta-blockers can be explained by 
multiple mechanisms. First, beta-blockers may exert their antiplatelet effect by a 
chemical interaction with the platelet cell membrane. The strength of this interac-
tion depends on the lipophilicity of the compound, and results in stabilisation of 
the platelet cell membrane, making it less sensitive to agonists.12 second, beta-2 
receptors on platelets may be blocked by non-selective beta-blockers. This would 
affect intra-platelet adenosine 3,5-cyclic monophosphate (cAMp) levels, which 
decreases calcium availability and subsequent activation of platelets.23 However, 
compared with the number of alpha-receptors per platelet, the number of beta-2 
receptors is small.24 Therefore it is more logical to assume that the beta-blockers 
exert part of their antiplatelet effect not directly, by binding platelet receptors, 
but indirectly, by decreasing plasma catecholamine levels. This is also supported 
by the fact that platelet aggregation was maximally inhibited by beta-blockers 
in experiments were epinephrine was used as an agonist (Figure 2). it is known 
that catecholamine levels reached in vivo potentiate platelet aggregation, thereby 
even overcoming inhibition of platelet aggregation by aspirin.23 interestingly, non-
selective beta-blockers reduce catecholamine levels more effectively than selective 
beta-blockers, which supports our finding that platelet aggregation is more ef-
fectively inhibited by non-selective beta-blockers.25,26 Third, high blood pressure 
activates platelets through multiple pathways, and a decrease of blood pressure 
itself could therefore decrease platelet aggregation.13
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strengths and limitations
A major strength of this meta-analysis is that we excluded in vitro studies from 
our analysis.27-33 in these studies, beta-blockers were added in concentrations that 
exceeded those currently used in medical practice, making it difficult to generalize 
the effects to the clinical situation. Another strength is that we did not exclude 
any type of study design. calculating effects sizes specific for each study design 
facilitated meta-analysis of the studies.
because different agonists induce different platelet activation pathways, this 
could influence the observed results. Therefore, before pooling all agonists, we 
first analysed the effect of beta-blockers on platelet aggregation separately by all 
agonists (Figure 2). This analysis showed that platelet aggregation was inhibited 
with the use of all agonists, and more pronounced with epinephrine. This could 
be expected because platelet sensitivity is modified by catecholamine levels.23 We 
think that pooling of all agonists to estimate the overall effect of beta-blockers 
on platelet aggregation is valid because all agonists showed a clear reduction in 
platelet aggregation. Moreover, Adp was the most frequently used agonist and did 
not show an extreme effect estimate which could have overestimated our overall 
pooled effect estimate.
A limitation of this meta-analysis is that the risk of bias of the included studies 
is quite high. We think this can be partly explained by the fact that most studies 
were performed in years when reporting according to international standards for 
clinical trials and observational studies was not yet established. However, we do 
not think that for example non-blinding would have affected our results, because 
platelet aggregation is not affected by placebo effects and it has been shown 
that open unblinded studies with objective endpoints yield the same results as 
double-blind placebo-controlled studies.34 Fifty percent of the included trials were 
designed as cross-over experiments, in which carry-over effects could influence 
the results.35 However, the treatment periods in all included cross-over studies 
were long enough to ensure adequate wash-out. This is supported by our finding 
that the pooled effect did not differ between short-term (<1 week) or long-term 
(>1 week) administration of beta-blockers. Finally, only 65% of the trials were 
randomized and only one trial described the randomisation procedure. However, 
in a sensitivity analysis we showed that the overall pooled effect size was robust 
with restriction to randomized studies only. The funnel plot showed evidence for 
small study effect, which might be explained by publication bias. nevertheless, 
cumulative meta-analysis still indicated a clear and statistically significant effect of 
beta-blockers on platelet aggregation. Finally, it is known that platelet aggrega-
tion is influenced by numerous characteristics, which were not all registered in the 
included studies. However, the majority of included studies were clinical trials, in 
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which randomization ensured that known and unknown variables affecting plate-
let aggregation were equally distributed over treatment groups and were kept 
constant during the trial. Therefore, confounding of our results by other platelet 
affecting variables is highly unlikely.
conclusion
in conclusion, this meta-analysis suggests that clinically used doses of beta-blockers 
reduce platelet aggregation. non-selective, lipophilic beta-blockers appear to re-
duce platelet aggregation most effectively. These findings may help to explain why 
some beta-blockers are more effective than others in preventing cvd.
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The main aim of this thesis was to assess the effect aspirin intake on awakening 
compared with intake at bedtime on blood pressure and the morning peak of 
platelet reactivity. The rationale behind these two research questions is described 
in detail in chapter 1. The design of our studies in chapter 3 and 4 was based on 
the specific methodological considerations of cross-over studies, which is reviewed 
in chapter 2. in this discussion we first apply these considerations on the design 
of our cross-over studies in this thesis. secondly, we will summarize the results of 
chapter 3 and 4, and discuss the implications of our findings. Finally, our studies 
on the influence of beta-blockers on platelet reactivity (chapter 6) and the role 
of platelet inflammatory markers in the development of recurrent cardiovascular 
events (chapter 5) are discussed.
cross-over sTudies
A cross-over design is an efficient alternative for a parallel-group design to study 
chronic disorders in which treatments have temporary effects. in general, only a 
quarter of the total group size is needed for cross-over studies compared with 
parallel group studies, saving costs and time. Treatments of blood pressure and 
platelet reactivity have temporary effects, and are therefore particularly suitable 
to study with a cross-over design. With a cross-over design, two major concerns 
have to be acknowledged: period-effects and carry-over effects. First, period-
effects can arise when the measured outcome changes over time. in chapter 3, 
for example, we measured blood pressure, which is known to increase with age. 
if all participants in our study would have received the same treatment order (e.g. 
3 months aspirin on awakening followed by 3 months aspirin at bedtime), this 
fixed change of blood pressure over time could distort our results. A solution to 
this problem is to randomize participants for the sequence of interventions. The 
fixed changes over time are then equally distributed over the interventions. so, 
randomisation is equally important in cross-over studies as in parallel-group stud-
ies, but for a different reason: in parallel-group studies randomization is used to 
achieve comparability between intervention groups, whereas in cross-over studies 
randomization is needed to achieve comparability between periods.
second, carry-over needs to be considered when using a cross-over design. A 
carry-over effect arises when an intervention in the previous period affects the 
results in the subsequent period. usually, a wash-out period is incorporated in 
cross-over studies to restore participants’ characteristics to their baseline state 
before the next intervention is started. However, in our study in chapter 3 a wash-
out period was unnecessary. To achieve adequate wash-out of any blood pressure 
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effect of the first intervention period before measurement in the second period, 
we assumed that aspirins’ effect on blood-pressure would not exceed the duration 
of the intervention periods (3 months). Furthermore, incorporation of a washout 
period would have been unethical, because patients used aspirin for prevention 
of cardiovascular disease. in our study in chapter 4 we did incorporate a wash-out 
period of 2 to 4 weeks. This was enough to ensure restoration of normal platelet 
reactivity, which takes 7-10 days, after the first intervention period with aspirin.
To summarize, we carefully considered the specific methodological issues of 
cross-over studies for the design of our studies in chapter 3 and 4, which enhanced 
the validity of our results.
Aspirin on AWAKeninG or AT bedTiMe?
bedtime aspirin to reduce blood pressure
in chapter 3 we studied whether intake of low-dose aspirin at bedtime compared 
with intake on awakening reduced blood pressure of patients with stable car-
diovascular disease. We randomized 290 patients, who already used aspirin for 
prevention of cardiovascular disease for a median duration of 6 years, to 3 months 
aspirin intake at bedtime followed by 3 months intake on awakening, or the op-
posite order. At the end of both intervention periods, 24-hour blood pressure was 
measured, which was complete for 263 patients. We found that aspirin intake at 
bedtime did not reduce 24-hour blood pressure compared with intake on awaken-
ing (difference systolic/diastolic: -0.1 [ci: -1.0; 0.9] / -0.6 [ci: -1.2; 0.0] mmHg).
Why did we find no effect on blood pressure?
previous studies suggested that aspirin reduces blood pressure when taken at 
bedtime instead of on awakening.1-4 Additionally, a biological plausible mecha-
nism was found: compared with intake on awakening, aspirin intake at bedtime 
reduced plasma renin activity, cortisol, dopamine and norepinephrine excretions 
over 24 hours.5 differences in patient characteristics and co-medication may ex-
plain why we did not find a blood pressure lowering effect of bedtime aspirin 
intake. All previous studies were performed in healthy subjects or patients with 
mild- or untreated hypertension or pregnancy. in contrast, patients in our study 
all had cardiovascular disease, already used aspirin before study entry and used 
concomitant antihypertensive drugs. yet, in our pre-specified subgroup analyses, 
based on the use of specific types of antihypertensive drugs, we also did not find 
a blood pressure lowering effect. importantly, even in the subgroup that did not 
use any blood pressure lowering drugs, there was no difference between intake 
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on awakening and at bedtime. This suggests that in patients already using aspirin 
for cardiovascular disease prevention, blood pressure is not affected by the time of 
aspirin intake, regardless of the concomitant use of antihypertensive drugs. These 
findings corroborate those of an earlier study, which also did not find a blood 
pressure lowering effect of bedtime aspirin intake among treated hypertensive 
patients.6 Another possible explanation for our findings is that the effect of aspirin 
intake at bedtime on blood pressure weakens over time because of increased arte-
rial stiffening and progressive atherosclerosis.7 Finally, non-compliance with the 
time of aspirin intake cannot explain our negative findings. A major strength of 
our study is that we registered the actual time of aspirin intake by electronic pill 
boxes. exclusion of participants who were less than 90% compliant did not affect 
our results. in summary, the contrasting results between previous studies and the 
present study might be explained by differences in study population. However, the 
patient populations of previous studies had low cardiovascular risk and therefore 
had no medical indication for aspirin.8 in low risk hypertensive patients, other 
antihypertensive medications, with less side effects than aspirin, are preferable. 
Therefore, a potential blood pressure lowering effect of bedtime aspirin intake is 
only clinically relevant in patients already using aspirin for cardiovascular disease 
prevention. Given the large size of our cross-over study and the absence of a blood 
pressure lowering effect of bedtime aspirin in any subgroup, no further studies are 
needed to assess the blood pressure lowering effect of bedtime aspirin.
bedtime aspirin to reduce morning platelet reactivity
in our study in chapter 3 we assessed the effect of taking aspirin at bedtime com-
pared with intake on awakening on platelet reactivity during morning hours in 
patients with established cardiovascular disease. platelet reactivity measurements 
were complete for 133 patients, a pre-specified subgroup of the total 290 random-
ized patients. Aspirin intake at bedtime reduced morning platelet reactivity with 
a mean of -22 verifynow-Aspirin reaction units (Aru) (ci -35 to -9). in chapter 3 
we measured platelet reactivity at only one time-point during the morning hours. 
To further assess the effect of bedtime aspirin intake on the circadian rhythm of 
platelet reactivity, we performed a 24-hour rhythm study in chapter 4. The main 
result of the study in chapter 4 was that bedtime aspirin intake reduced two coX-
1-dependent assays, namely verifynow-Aspirin (-23 Aru [ci -50 to 4]) and sTxb2 
(-1.8 ng/ml [ci -2.8 to -0.8]), during morning hours. The magnitude of this reduction 
is similar to the results in chapter 3. in contrast, aspirin intake at bedtime versus on 
awakening did not affect coX-1-independent assays.
A possible explanation is that platelet activation by coX-1-independent pathways 
is not affected by aspirin in general. However, this also raises questions about the 
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relative clinical importance of coX-1-dependent and coX-1-independent platelet 
reactivity assays, which will be discussed below. Finally, the studies in chapter 3 and 
4 included patients with chronic cardiovascular disease and healthy participants 
respectively, whereas numerous patients take aspirin in combination with other 
antiplatelet drugs in the acute phases of cardiovascular disease. so, the results of 
our studies cannot be generalized to patients in the acute phase of cardiovascular 
disease. However, a previous study found that, compared with morning intake, the 
morning surge of platelet aggregation was also decreased by the combined intake 
of aspirin and clopidogrel at bedtime.9
in summary, these studies suggest that platelet reactivity during the high risk 
morning hours can be reduced by taking aspirin at bedtime instead of on awaken-
ing. next, we will discuss the clinical implications of these results.
should we advise patients to take aspirin at bedtime?
Safety of bedtime aspirin
The majority (70%) of the patients in our study in chapter 3 took aspirin on awak-
ening before study entry. should we advise these patients to switch to bedtime 
intake, based on the studies presented in this thesis? The medical principle ‘first 
do no harm’ applies to this suggested intervention. in our study we compared the 
number of side effects after aspirin intake on awakening with intake at bedtime. 
We observed that drop-out of patients (n=26) was not related to the timing of 
aspirin intake, and that the frequency of side-effects was not increased by aspirin 
intake at bedtime. in line with this observation, previous studies suggest that 
gastric vulnerability to aspirin is lower during night than during the day.10, 11 in 
summary, with respect to harms, it seems safe to advise patients to take aspirin at 
bedtime.
Clinical effect of bedtime aspirin
When doing no harm, is it beneficial for patients to take aspirin at bedtime instead 
of on awakening? What are the clinical implications of switching to bedtime as-
pirin? no previous study evaluated the effect of this intervention. in our studies 
we did not follow patients for the occurrence of clinical end points. in chapter 4 
we observed that bedtime aspirin intake only affects circadian rhythm of coX-1-
dependent assays, while in a previous study in aspirin treated patients, poor clinical 
outcomes were associated with both high values of coX-1-dependent (sTxb2) and 
coX-1-independent assays.12 Moreover, acute arterial thrombosis is a multifactorial 
process and coX-1 only affects a part of platelet reactivity in vivo. similarly, the 
morning peak of cardiovascular events is also caused by multiple factors (Figure 1). 
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We therefore do not expect that more efficient coX-1-dependent platelet inhibi-
tion abolishes the morning peak of cardiovascular events completely.13 still, the 
specific expected benefit of reducing coX-1-dependent platelet reactivity might 
be derived in two ways: 1) from previous observational studies and 2) by calculat-
ing the possible benefit derived from known cardiovascular disease statistics. First, 
it has been shown that the risk of recurrent cardiovascular events is increased in 
patients with higher verifynow-aspirin platelet reactivity values.14, 15 stable cardio-
vascular disease patients with verifynow-Aspirin platelet reactivity >550 Aru had 
an absolute risk of 15.6% for developing the composite cardiovascular endpoint, 
whereas this was only 5.3% in patients with Aru values <550.14 in another study, 
the absolute risk for the primary endpoint (all-cause death and recurrent cardio-
vascular events) was 13.3% in patients >454 Aru and 5.9% in patients <454 Aru.15 
These observational studies suggest that already a modest reduction in coX-1- 
dependent platelet reactivity, as found in our studies in chapter 3 and 4, could 
result in clinical benefit.
second, the clinical benefit can be calculated with known cardiovascular disease 
statistics.16 These statistics, from the united states, show that each year 280 000 
patients develop a recurrent cardiovascular event. on average, this equals 767 
events each day. With the known excess of 40% during the morning hours (6-12 
AM), this would mean that 241 events occur from 6 to 12 AM, and 526 during the 
40%






















Figure 1 – distribution of acute cardiovascular events over the day in 6 hour time windows. The 
horizontal line corresponds to the number expected cardiovascular events if events occurred 
evenly throughout the day. However, a clear peak of cardiovascular events during the morning 
hours (6-12 AM) is present. Multiple mechanisms, including the morning peak of platelet reac-
tivity, probably contribute to this peak. (Adapted from: elliot WJ, Am J Hypertens 2001;14:291-
95s).
106 chapter 7
rest of the day. compared with the other three 6-hour time periods, the absolute 
excess of recurrent cardiovascular events due to the morning peak equals 66 events 
per day. if aspirin intake at bedtime reduces platelet reactivity during the morning 
hours, and thereby would reduce the morning peak of cardiovascular events by 
10%, this would lead to a reduction of 6.6 events per day and 2427 events per year 
in the united states. With 50% reduction of the morning peak, this equals 12 133 
events per year. The total number of recurrent cardiovascular events would then 
be reduced from 280 000 to 267 867 (Figure 2).
Given the high incidence of cardiovascular disease, already a modest relative 
reduction of the morning peak would lead to a large absolute reduction of car-
diovascular events on a population level. However, although switching to bedtime 
aspirin intake is a simple intervention, future clinical trials need to be performed 
to validly quantify the reduction of cardiovascular events.
To summarize, studies in this thesis suggest that, for patients who already take 
aspirin on a daily basis for cardiovascular disease prevention, switching to aspirin 
intake at bedtime is safe and potentially beneficial because platelet reactivity dur-
ing the high risk morning hours is reduced by taking aspirin at bedtime instead 
of on awakening. However, future studies are needed to evaluate with which 
magnitude this reduction in platelet reactivity affects clinical outcomes.


































Figure 2 – estimation of the effect of bedtime aspirin intake on the incidence of recurrent heart 
attacks in the united states.
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bAsAl plATeleT AcTiviTy And recurrenT cArdiovAsculAr evenTs
After a first cardiovascular event, classical risk factors (e.g. blood pressure, choles-
terol) are aggressively treated. still, 20% to 40% of all patients develop a recur-
rent cardiovascular event.17 so, other risk factors are likely to play a role in the 
development of a recurrent event. basal platelet activity has been proposed as 
one of those mechanisms.18, 19 in chapter 5 we studied whether increased basal 
platelet activity, as measured by the chemokines nAp-2, cXcl4 and rAnTes, is 
associated with the incidence of recurrent cardiovascular events. These platelet 
chemokines interact with inflammatory cells in the progression of atherosclerosis 
and leukocyte recruitment in acute arterial thrombi.20, 21 The study of Myocardial 
infarctions leiden (sMile) follow-up study was used, which is a cohort study of men 
(n=542) who experienced a myocardial infarction (Mi) between 1990 and 1996. 
basal platelet activity markers were measured in blood drawn after (median 2.6 
years) the first Mi, and patients were followed for a median of 9.2 years, register-
ing recurrent major adverse cardiovascular events (rMAce). during follow-up 254 
(47%) patients developed at least one rMAce. The main finding was that patients 
with an increased basal platelet activity, defined as >90th percentile, were not at 
increased risk of rMAce (adjusted hazard ratios: nAp-2: 1.1 [95% ci 0.8-1.7]; cXcl4: 
1.2 [0.8-1.8]; rAnTes 1.2 [0.8-1.8]).
These findings contradict previous studies, in which basal levels of these platelet 
inflammatory markers appeared to play a role in the development of first and re-
current cardiovascular events.18, 19, 22-25 We suggest two explanations for this finding. 
First, our study population represented a group of stable cardiovascular disease 
patients who survived a first Mi, whereas patients in previous studies were studied 
in an acute setting.18, 19, 23-25 These studies showed that platelet chemokine markers 
increase when an acute cardiovascular event occurs, and decrease after the event. 
it is possible that platelet derived chemokines are merely a marker of acute platelet 
activation, and as such do not contribute to acute arterial thrombus formation. 
second, basal platelet activity might play a more dominant role in the development 
of cardiovascular events in patient populations with a low prevalence of classical 
risk factors. When classical risk factors are absent, it is likely that other factors, 
such as inflammatory platelet markers, contribute to acute thrombus formation. 
This theory is supported by the previous finding that basal levels of inflammatory 
platelet markers increased the risk of myocardial infarction in young women.22
We conclude that basal platelet inflammatory markers are not associated with 
recurrent cardiovascular events in men who survived a myocardial infarction. lev-
els of platelet inflammatory markers might still affect the risk of cardiovascular 
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events, but this probably depends on the prevalence of classical cardiovascular risk 
factors in the studied population.
beTA-blocKers And plATeleT reAcTiviTy
Following international guidelines, beta-blockers are frequently prescribed to 
patients with cardiovascular disease.26 For example, in our clinical trial in chapter 3, 
53% of the patients used a beta-blocker. platelet reactivity is affected by numerous 
characteristics.27, 28 because beta-adrenergic receptors are present on human plate-
lets, an effect of beta-blockers on platelet reactivity may be expected.29 However, 
the existence and magnitude of this effect still was unclear. in a systematic review 
and meta-analysis, described in chapter 6, we synthesized all currently available 
evidence of the effect of beta-blockers on platelet reactivity. We included 31 stud-
ies (28 trials, 3 observational studies) in which a total of 454 participants were 
studied. The main finding was that beta-blocker use reduced platelet aggrega-
tion with 13% (95% ci 8-17%). interestingly, we found that this effect was most 
pronounced with epinephrine-induced platelet aggregation, which suggests a role 
of platelet beta-adrenergic receptors or catecholamine levels as underlying mecha-
nisms. Furthermore, non-selective and lipophilic beta-blockers decreased platelet 
aggregation more than selective and non-lipophilic beta-blockers. A limitation was 
that most studies were of moderate to low methodological quality. For example, 
only 20/28 (71%) of all trials were randomized and only one trial described the 
randomisation procedure. However, in a sensitivity analysis of randomized studies 
only, the effect size remained similar. Additionally, we suspected publication bias, 
because the funnel plot revealed the absence of small studies with negative results. 
To estimate the magnitude of this bias, we performed a cumulative meta-analysis 
based on study precision. Although the overall effect was attenuated, this analysis 
still indicated that beta-blockers reduce platelet aggregation. Another limitation 
is that the included studies solely used light transmission aggregometry (lTA) to 
assess platelet aggregation, whereas multiple other assays are available nowadays. 
However, lTA is the historical golden standard to test platelet aggregation, and 
correlates with the measurements we used in chapters 3 and 4 (verifynow and 
sTxb2).
30 Additionally, a reduction of platelet aggregation was observed with the 
use of different antagonists, representing the most important platelet activation 
pathways.31 A major strength of this meta-analysis is that we excluded in vitro 
studies from our analysis. in these studies, beta-blockers were added in concentra-
tions that exceeded those currently used in medical practice, making it difficult to 
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generalize the effects to the clinical situation. Another strength is that we did not 
exclude any type of study design.
The inhibition of platelet aggregation by beta-blockers can be explained by mul-
tiple mechanisms. First, beta-blockers may chemically interact with the lipophilic 
platelet cell membrane, which could result in stabilisation of the cell membrane 
and thereby make platelets less sensitive to stimuli.32 This is supported by our 
finding that lipophilic beta-blockers reduce platelet aggregation more than non-
lipophilic beta-blockers. second, beta-blockers may affect platelets directly, by 
binding platelet receptors, or indirectly, by decreasing platelet potentiating plasma 
catecholamine levels.29 However, the number of beta-2 receptors on platelets is 
small.33 Therefore it is more logical to assume that the beta-blockers exert part 
of their antiplatelet effect by decreasing plasma catecholamine levels. This is also 
supported by our findings that platelet aggregation was maximally inhibited by 
beta-blockers in experiments were epinephrine was used as an antagonist. Third, 
high blood pressure activates platelets through multiple pathways, and a decrease 
of blood pressure itself could therefore decrease platelet aggregation.34
in conclusion, our meta-analysis in chapter 6 suggests that besides beneficial 
effects on heart rate, blood pressure and myocardial oxygen demand, part of 
the protective effect of beta-blockers could be the result of platelet aggregation 
inhibition.
conclusions
in summary, aspirin intake at bedtime did not reduce blood pressure of patients 
with stable cardiovascular disease. However, the studies in this thesis suggest that 
platelet reactivity during the high risk morning hours can be reduced by aspirin 
intake at bedtime. Future studies should evaluate whether this simple interven-
tion indeed leads to a reduction of cardiovascular events. The study on basal 
levels of platelet inflammatory markers does not support previous evidence that 
these markers contribute to the development of recurrent cardiovascular events 
in a high risk cardiovascular disease population. However, platelet reactivity, as 
measured in our studies on the effect of aspirin intake at bedtime, was associated 
with cardiovascular events in previous observational studies. in a meta-analysis, 
we suggest that beta-blockers, which are frequently prescribed to patients with 
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cHApTer 3, AppendiX TAble 1
Appendix table 1. Mean 24-hour, day- and night ambulatory blood pressure values (mmHg) ac-
cording to time of aspirin administration in the secondary analysis population (n=150)
Aspirin on 
awakening
Aspirin at bedtime Mean difference
(bedtime – awakening)
[95% ci]*
24-hour sbp 125 ± 10 125 ± 9 0.0 [-1.1 to 1.1]
24-hour dbp 78 ± 8 77 ± 8 -0.4 [-1.2 to 0.3]
day sbp 129 ± 10 129 ± 10 0.1 [-1.2 to 1.3]
day dbp 81 ± 9 80 ± 8 -0.5 [-1.3 to 0.2]
night sbp 115 ± 12 115 ± 12 0.0 [-1.5 to 1.5]
night dbp 68 ± 10 68 ± 9 -0.2 [-1.2 to 0.7]
*Mean difference and 95% ci obtained with paired t-tests. values are mean ± standard devia-
tion.
sbp: systolic blood pressure; dbp: diastolic blood pressure; ci: confidence interval
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cHApTer 3, AppendiX TAble 2
Appendix table 2. side effects and relation with timing of aspirin intake of subjects that did not 
complete study follow-up (n=26)
Patient code Period of 
drop-out
Timing of Aspirin 
intake at drop-out
reason drop-out related to 
side effect 
of aspirin
105 1 At bedtime stopped aspirin use after advise 
cardiologist
no
113 1 on awakening stomach pain after switch from 
evening intake to intake on 
awakening
yes
132 1 At bedtime study participation too aggravating no
151 1 on awakening Withdrawal of consent to participate 
in other clinical trial
no
173 1 At bedtime study participation too aggravating no
180 1 At bedtime study participation too aggravating no
250 1 on awakening stomach pain after switch from 
evening intake to intake on 
awakening
yes
251 1 At bedtime study participation too aggravating no
327 1 on awakening study participation too aggravating no
329 1 At bedtime stopped aspirin use after head 
trauma; advise of first aid physician
no
365 1 At bedtime study participation too aggravating no
436 1 on awakening study participation too aggravating no
447 1 on awakening study participation too aggravating no
455 1 At bedtime study participation too aggravating no
462 1 At bedtime study participation too aggravating no
203 2 At bedtime study participation too aggravating no
271 2 At bedtime study participation too aggravating no
334 2 on awakening stopped aspirin use after advise 
cardiologist
no
344 2 on awakening study participation too aggravating no
366 2 on awakening switch to vitamin k antagonist instead 
of aspirin after advise cardiologist
no
368 2 on awakening switch to vitamin k antagonist instead 
of aspirin after advise cardiologist
no
387 2 At bedtime switch to vitamin k antagonist instead 
of aspirin after advise cardiologist
no
405 2 At bedtime did not want to take aspirin at 
bedtime due to practical reasons
no
417 2 on awakening study participation too aggravating no
465 2 At bedtime Headache after switch from morning 
intake to intake at bedtime
possible
437 2 on awakening study participation too aggravating no
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cHApTer 3, AppendiX TAble 3
Appendix table 3. self-reported side effects of randomized study subjects at baseline and 










dyspepsia 15 (5.2) 12 (4.5) 12 (4.5) 1.00
nausea 8 (2.8) 4 (1.5) 9 (3.4) 0.18
Heartburn 27 (9.3) 16 (6.1) 20 (7.6) 0.50
nose bleeding 13 (4.5) 9 (3.4) 6 (2.3) 0.55
bruises 45 (15.5) 32 (12.1) 35 (13.3) 0.75
bloody stool 4 (1.4) 5 (1.9) 5 (1.9) 1.00
*p-value obtained by Mcnemar’s test
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cHApTer 6, AppendiX MeTHods 1
overview of the complete search strategy per database. results for search on June 
1st 2013:
pubmed search strategy (331 hits)
(“platelet function Tests”[Mesh] or “platelet function Tests”[ti] or 
“verifynow”[tiab] or “pFA-100”[tiab] or “multiple electrode aggregometry”[tiab] 
or “light transmission aggregometry”[tiab] or “serum thromboxane”[tiab] or 
“platelet Aggregation”[Majr] or “platelet Aggregation”[ti] or “platelet Aggre-
gation inhibitors”[Majr] or “antiplatelet”[ti] or “platelet Adhesiveness”[Majr] 
or “platelet Adhesiveness”[ti] or “platelet Antiaggregant”[ti] or “platelet 
Antiaggregants”[ti]) And (“adrenergic beta-antagonists”[Majr] or “adren-
ergic beta-antagonists”[ti] or “beta blockers”[ti] or “beta-blockers”[ti] or 
“betablockers”[ti] or “beta blocker”[ti] or “beta-blocker”[ti] or “betablocker”[ti] 
or “adrenergic beta-antagonists”[pharmacological Action] or “β blocker”[ti] 
or “β-blocker”[ti] or “β blockers”[ti] or “β-blockers”[ti] or “beta-Adrenergic 
blocking”[ti])
embase search strategy (734 hits)
(“platelet function test*”.ti,ab. or “platelet aggregation” .ti,ab. or exp throm-
bocyte aggregation/ or “verifynow”.ti,ab. or “pFA-100”.ti,ab. or “multiple 
electrode aggregometry”.ti,ab. or “light transmission aggregometry”.ti,ab. or 
“serum thromboxane”.ti,ab. or “platelet adhesion”.ti,ab. or exp thrombocyte 
adhesion/ or antiplatelet*.ti,ab. or “platelet adhesiveness”.ti,ab. or “platelet 
antiaggregant*”.ti,ab.)And (exp *beta adrenergic receptor blocking agent/ or 
“adrenergic beta-antagonist*”.ti. or “beta blocker*”.ti. or “beta-blocker*”.ti. 
or “betablocker*”.ti. or “beta-Adrenergic blocking”.ti.)
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cHApTer 6, AppendiX MeTHods 2
calculation of effect size estimates (sMds) and standard errors (ses). Formulas used 
to calculate sMds and ses for each study design:
study Design effect size estimate (smD) standard error (se) of smD
Unpaired
Two-group trial
Chapter 6, appendix methods 2 
Calculation of effect size estimates (SMDs) and standard errors (SEs). Formulas used to calculate 
SMDs and SEs for each study design: 
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If not reported, we calculated SDpre  assuming equal variances over treatment periods and using the 
mean correlation of the other included paired studies (mean correlation 0.54):   SDpre = �
𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
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  st r iz   iff r c ; D,i   iff r c  st  r -t st i  i t rv ti  r ; 
D,p   iff r c  st  r -t st i  l c  r ; e   i  x s  r ; ne   i  
- x s  r ;  post   st-t st; pre   r -t st. 
S pooled  ol  st r  vi ti  t s li , c lc l t  s  
(𝑁𝑁𝑖𝑖 1)𝑆𝑆𝐷𝐷𝑖𝑖2 (𝑁𝑁𝑝𝑝 1)𝑆𝑆𝐷𝐷𝑆𝑆2
𝑁𝑁𝑡𝑡𝑝𝑝𝑡𝑡
 
S ne  st r  vi ti  i  - x s ; S pre  st r  vi ti  r -t st. 
tot  t t l r f s j cts ; i  r f s j cts i  i t rv ti  r ; p  r f 
s j cts i  l c  r ; e r f s j cts i  t  x s  r ; ne  r f s j cts i  
- x s  r . 
  c rr l ti , c lc l t  s 
𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝        2  𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝          2   𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
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2 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
     it  S diff  st r  vi ti  f t  
iff r c s. 
If t r rt ,  c lc l t  S pre  ss i  l v ri c s v r tr t t ri s  si  t  
 c rr l ti  f t  t r i cl  ir  st i s (  c rr l ti  . ):   S pre  
𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑





ter , e i  et s  
Calculation of ef ect size esti ates (S Ds) and standard er ors (SEs). For ulas used to calculate 
S Ds and SEs for each study design: 




T o-group trial 
 
 


















Paired   






  2(1 𝜌𝜌) 






  2(1 𝜌𝜌) 
 
S D = standardized ean dif erence; D,i = ean dif erence post – pre-test in intervention group; 
D,p = ean dif erence post – pre-test in placebo group; e = ean in exposed group; ne = ean in 
non-exposed group; post = ean post-test; pre = ean pre-test. 




SDne = standard deviation in non-exposed; SDpre= standard deviation pre-test. 
Ntot = total nu ber of subjects ; Ni = nu ber of subjects in intervention group; Np= nu ber of 
subjects in placebo group; Ne=nu ber of subjects in the exposed group; Nne= nu ber of subjects in 
non-exposed group. 
ρ = cor elation, calculated as 
𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝  2+ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝  2  − 𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑 𝑑𝑑
  2 
2 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
 ith SDdif  = standard deviation of the 
dif erences. 
If not reported, e calculated SDpre  assu ing equal variances over treat ent periods and using the 
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SMD = standardized mean difference; MD,i = mean difference post – pre-test in intervention group; 
MD,p = mean difference post – pre-test in placebo group; Me = mean in exposed group; Mne = mean in 
non-exposed group;  Mpost = mean post-test; Mpre = mean pre-test. 




SDne = standard deviation in non-exposed; SDpre= standard deviation pre-test. 
Ntot = total number of subjects ; Ni = number of subjects in intervention group; Np= number of 
subjects in placebo group; Ne=number of subjects in the exposed group; Nne= number of subjects in 
non-exposed group. 
ρ = correlation, calculated as 
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     with SDdiff = standard deviation of the 
differences. 
If not reported, we calculated SDpre  assuming equal variances over treatment periods and using the 
mean correlation of the other included paired studies (mean correlation 0.54):   SDpre = �
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S  = standardized ean difference; D,i = ean difference post – pre-test in intervention group; 
D,p = ean difference post – pre-test in placebo group; e = ean in exposed group; ne = ean in 
non-exposed group;  post = ean post-test; pre = ean pre-test. 




S ne = standard deviation in non-exposed; S pre= standard deviation pre-test. 
tot = total nu ber of subjects ; i = nu ber of subjects in intervention group; p= nu ber of 
subjects in placebo group; e=nu ber of subjects in the exposed group; ne= nu ber of subjects in 
non-exposed group. 
ρ = correlation, calculated as 
𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝        2+ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝          2  − 𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
          2 
2 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
     ith S diff = standard deviation of the 
differences. 
If not reported, e calculated S pre  assu ing equal variances over treat ent periods and using the 
ean correlation of the other included paired studies ( ean correlation 0.54):   S pre = 
𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑





sMd = standardized i ference; MD,i = m an d ff ence post – pre-test in 
intervention group; MD,p = mean difference post – pre-test in placebo group; Me = 
mean in xposed group; Mne = mean in non-exposed group; Mpost = mean post-test; 
Mpre = mean pre-test.
SDpooled = pooled standard deviation at baseline, calculated as 
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SMD = standardized mean diff rence; MD,i = mean difference post – re-t st in intervention group; 
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differences. 
If not reported, we calculated SDpre  assuming equal variances over treatment periods and using the 
mean correlation of the other included paired studies (mean correlation 0.54):   SDpre = �
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ρ = correlation, calculated as 
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SMD = sta dardized  if r c ; MD,i = m an difference post – pre-test in intervention group; 
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SMD = standardized mean difference; MD,i = mean difference post – pre-test in interventio  group; 
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non-exposed group. 
ρ = correlation, calculated as 
𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝        2+ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝          2  − 𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑
          2 
2 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝 ∗ 𝑆𝑆𝐷𝐷𝑝𝑝𝑝𝑝𝑝𝑝𝑝𝑝
     with SDdiff = standard deviation of the 
differences. 
If not reported, we calculated SDpre  assuming equal variances over treatment p riods nd using the 
mean correlation of the other included pai d studies (mean correlation 0.54):   SDpre = �
𝑆𝑆𝐷𝐷𝑑𝑑𝑑𝑑𝑑𝑑𝑑𝑑

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































cHApTer 6, AppendiX FiGure 1
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Appendix figure 1 – risk of bias assessment. Methodological quality graphs: review authors’ 
judgements about each methodological quality item presented across included trials (panel a) 
and observational studies (panel b).
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Appendix figure 2 – cumulative meta-analysis based on study precision.
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Het doel van dit proefschrift was om het effect van aspirine inname ’s ochtends of 
‘s avonds op de bloeddruk en ochtendpiek van bloedplaatjesactiviteit te onder-
zoeken. de achtergrond hiervan is uitgebreid beschreven in hoofdstuk 1 en zal 
hieronder kort worden samengevat.
onze studies in hoofdstuk 3 en hoofdstuk 4 waren ‘cross-over’ studies. speci-
fieke methodologische kenmerken hiervan zijn beschreven in hoofdstuk 2. in deze 
samenvatting worden eerst de specifieke kenmerken van cross-over studies toege-
past op de studies in dit proefschrift. daarna worden de resultaten van hoofdstuk 
3 en hoofdstuk 4 samengevat en bespreken wij conclusies en aanbevelingen. Tot 
slot vatten wij de bevindingen over de invloed van bloedplaatjes markers op het 
recidief risico hart- en vaatziekten (hoofdstuk 5) en de invloed van bèta-blokkers 
op bloedplaatjesactiviteit (hoofdstuk 6) samen.
cross-over sTudies
cross-overstudies zijn veelal goedkoper en efficiënter dan studies met parallelle 
groepen. in een cross-overstudie krijgt elk individu in opeenvolgende perioden alle 
behandelingen die onderzocht worden, waarbij de uitkomsten gemeten worden 
aan het eind van elke periode. de effecten worden dus vergeleken per individu in 
plaats van tussen groepen individuen. er zijn echter wel specifieke voorwaarden 
voor het uitvoeren van een cross-overstudie. cross-overstudies kunnen gebruikt 
worden bij het bestuderen van chronische aandoeningen waarbij het effect van 
de behandeling tijdelijk is. behandeling van bloeddruk en bloedplaatjesactiviteit, 
onderzocht in hoofdstuk 3 en hoofdstuk 4, zijn hiervan goede voorbeelden. de 
resultaten	van	een	cross-over	 studie	kunnen	worden	beïnvloed	door	periode-ef-
fecten en ‘carry over’-effecten. periode-effecten kunnen ontstaan als een uitkomst 
verandert over de tijd. in hoofdstuk 3 bijvoorbeeld werd bloeddruk gemeten, en 
die stijgt met de leeftijd. Als alle deelnemers in onze studie alle behandelingen in 
dezelfde volgorde zouden hebben gekregen (bijvoorbeeld: 3 maanden aspirine ’s 
ochtends, gevolgd door 3 maanden aspirine ’s avonds), zou de vaste stijging van 
bloeddruk	over	de	tijd	onze	resultaten	kunnen	beïnvloeden.	Een	oplossing	hiervoor	
is om deelnemers te randomiseren voor de volgorde van de interventie. de vaste 
stijging van bloeddruk over de tijd wordt dan gelijk verdeeld over de interventies. 
Kortom, randomisatie is even belangrijk in cross-over studies als in parallelle-groep 
studies, maar vanwege een andere reden: randomisatie in parallelle-groep studies 
wordt gebruikt om vergelijkbaarheid tussen de interventiegroepen te bereiken, 
terwijl randomisatie bij cross-over studies nodig is om vergelijkbaarheid tussen de 
interventieperioden te bereiken.
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verder moet er bij de opzet van een cross-over studie gedacht worden aan 
‘carry-over’ effecten. Als behandelingen vergeleken worden in opeenvolgende 
perioden kan het voorkomen dat de behandeling van periode 1 nog doorwerkt in 
periode 2. dit wordt het ‘carry-over’-effect genoemd. een manier om dit effect te 
voorkomen is door tussen de behandelperioden een uitwasperiode (‘wash-out’) in 
te bouwen waarin geen behandeling wordt gegeven. Het idee erachter is dat de 
metingen	in	de	volgende	periode	niet	meer	worden	beïnvloed	door	de	behande-
ling in de voorafgaande periode omdat het effect daarvan uitgewerkt is tijdens 
de uitwasperiode. echter, in de studie in hoofdstuk 3 was een uitwasperiode niet 
nodig. om een goede wash-out te bewerkstelligen van het effect van aspirine op 
de bloeddruk in de eerste periode werd aangenomen dat het effect van aspirine 
op de bloeddruk niet langer zou duren dan de duur van de interventieperiode (3 
maanden). ook zou een uitwasperiode in deze studie onethisch zijn geweest, om-
dat patiënten aspirine gebruikten ter preventie van hart- en vaatziekten. in onze 
studie in hoofdstuk 4 werd wel een uitwasperiode ingebouwd. de duur hiervan, 2 
tot 4 weken, was voldoende om de normale bloedplaatjesactiviteit te herstellen (7 
tot 10 dagen) na aspirine inname tijdens de eerste interventieperiode.
samenvattend hebben wij rekening gehouden met de specifieke methodologi-
sche kenmerken van cross-over studies bij de opzet van de studies in hoofdstuk 3 
en hoofdstuk 4, wat de validiteit van deze studies ondersteunde.
Aspirine ’s ocHTends oF ’s Avonds?
een lage dosis aspirine (carbasalaatcalcium of acetylsalicylzuur) is de hoeksteen in 
de behandeling van hart- en vaatziekten: het verlaagt het risico op het opnieuw 
optreden van hart- en vaatziekten met 25%. daarmee is het een van de meest 
effectieve geneesmiddelen die we kennen. de werking van aspirine berust op het 
remmende effect op de bloedplaatjes. Als bloedplaatjes samenklonteren en een 
stolsel vormen in een slagader kan dit een hart- of herseninfarct tot gevolg heb-
ben. Aspirine remt de klonterneiging van bloedplaatjes en voorkomt daarmee een 
gedeelte van de hart- en herseninfarcten.
in eerdere studies werd echter nog een effect van aspirine gevonden: aspirine 
kan de bloeddruk verlagen als het ’s avonds wordt ingenomen in plaats van ’s 
ochtends. dit verassende effect werd gevonden in studies met gezonde proef-
personen, zwangeren of patiënten met licht verhoogde bloeddruk. Aangezien 
aspirine ook bijwerkingen kent, dient het alleen te worden voorgeschreven als 
het voordelige effect ervan opweegt tegen het risico op bijwerkingen. Alleen bij 
patiënten met hart- en vaatziekten is dit het geval. voor deze patiënten is een 
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bloeddruk verlagend effect van aspirine waarschijnlijk ook voordelig, aangezien 
bloeddruk een van de belangrijkste risicofactoren is voor het optreden van hart- en 
vaatziekten.
Avond-aspirine om bloeddruk te verlagen
in hoofdstuk 3 is onderzocht of aspirine-inname ’s avonds in plaats van ’s ochtends 
de bloeddruk verlaagt van patiënten die dagelijks aspirine gebruiken ter preventie 
van hart- en vaatziekten. Hiervoor werden uit huisartsenpraktijken in de omgeving 
leiden 290 patiënten willekeurig ingedeeld in twee groepen. de eerste groep 
gebruikte 3 maanden aspirine ’s ochtends, gevolgd door 3 maanden aspirine ’s 
avonds. de tweede groep gebruikte 3 maanden aspirine ’s avonds, gevolgd door 3 
maanden aspirine ’s ochtends. Aan het eind van elke 3 maanden werd gedurende 
24 uur de bloeddruk gemeten en werden bijwerkingen van aspirine geregistreerd. 
de bijwerkingen met aspirine-inname ’s avonds kwamen gemiddeld niet vaker voor 
dan met inname ’s ochtends. voor 263 patiënten waren de bloeddrukmetingen 
compleet. We constateerden dat de gemiddelde bloeddruk over 24 uur niet lager 
was met avond-inname van aspirine dan met ochtend-inname (gemiddeld verschil 
systolisch / diastolisch: -0.1 [ci: -1.0; 0.9] / -0.6 [ci: -1.2; 0.0] mmHg). ook was er 
geen verschil in bloeddruk over de dag- en nacht, en bij subgroepen patiënten 
die wel of geen antihypertensiva gebruikten. een mogelijke verklaring voor onze 
negatieve bevinding wat betreft bloeddruk is dat het bloeddrukverlagend effect 
van avond-aspirine afneemt naarmate patiënten langer aspirine gebruiken door 
toename van stijfheid van de bloedvaten. Geconcludeerd kan worden dat inname 
van aspirine ’s avonds in plaats van ’s ochtends de bloeddruk niet verlaagt van 
patiënten die aspirine gebruiken ter preventie van hart- en vaatziekten. Gezien 
de hoge validiteit van ons onderzoek en de afwezigheid van enig bloeddrukverla-
gend effect van avond-aspirine is er geen toekomstig onderzoek meer nodig naar 
het bloeddrukverlagende effect van avond-aspirine in patiënten die al aspirine 
gebruiken.
Avond-aspirine om de ochtendpiek van bloedplaatjesactiviteit te verlagen
eerst zal kort de achtergrond worden samengevat, waarna de resultaten van de 
studies in hoofdstuk 3 en hoofdstuk 4 worden besproken.
de werking van aspirine berust op het remmende effect op de bloedplaatjes. 
deze remming is onomkeerbaar voor de gehele levensduur van elk bloedplaatje 
(7-10 dagen). Toch moet aspirine elke dag worden ingenomen, omdat dagelijks 
ongeveer 10% van de bloedplaatjes worden vernieuwd. ook is bekend dat de 
bloedplaatjesactiviteit een 24-uurs ritme volgt, met een piek in de ochtenduren. 
deze piek valt samen met de piek in het optreden van hart- en vaatziekten van 
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6-12 uur ‘s ochtends. de verhoogde activiteit van bloedplaatjes in de ochtenduren 
draagt dus waarschijnlijk bij aan die van hart- en vaatziekten in de ochtend. na 
inname remt aspirine bloedplaatjes die op dat moment aanwezig zijn in het bloed, 
maar wordt binnen 30 minuten afgebroken en uitgescheiden uit het lichaam. Alle 
bloedplaatjes die daarna worden aangemaakt zijn dus ongeremd door aspirine. de 
meeste mensen nemen aspirine ’s ochtends in. eerder onderzoek toonde aan dat, 
bij aspirine inname in de ochtend, de bloedplaatjesactiviteit de volgende ochtend 
(vlak voor inname van de volgende aspirine) onvoldoende geremd werd in 25% van 
de patiënten die dagelijks aspirine slikten. dit terwijl juist in de ochtenduren een 
optimale remming gewenst is vanwege de verhoogde kans op hart- en vaatziekten 
in de ochtend. een manier om de remming van bloedplaatjes in de ochtend te 
verbeteren is wellicht door aspirine ’s avonds in te nemen in plaats van ’s ochtends. 
dit zou kunnen zorgen voor een verlaging van de ochtendpiek in bloedplaatjesac-
tiviteit en daarmee mogelijk ook voor een verlaging van het optreden van hart- en 
vaatziekten in de ochtend. of de ochtendpiek van bloedplaatjesactiviteit verlaagd 
kan worden door aspirine ’s avonds in te nemen in plaats van ‘s ochtends is nog 
niet eerder onderzocht.
in hoofdstuk 3 werd bij een gedeelte van de patiënten (n=133) bloedplaatjesac-
tiviteit in de ochtenduren gemeten. de bloedplaatjesactiviteit werd gemeten met 
behulp van een apparaat waarmee de klonterneiging van bloedplaatjes uitgedrukt 
werd in een getal (aspirine reactie units; Aru). een hogere waarde betekent een 
hogere bloedplaatjesactiviteit. Wij constateerden dat de bloedplaatjesactiviteit 
in de ochtenduren lager was als aspirine ’s avonds werd ingenomen (gemiddeld 
verschil: 22 Aru [95% betrouwbaarheidsinterval (bi): -35 tot -9]). een beperking 
van dit onderzoek was dat er maar één meting tijdens de ochtenduren kon wor-
den verricht, terwijl bekend is dat bloedplaatjesactiviteit een 24-uurs ritme volgt. 
daarom werd een 24-uurs ritme studie uitgevoerd, die beschreven is in hoofdstuk 
4. veertien gezonde vrijwilligers namen 2 weken aspirine ’s ochtends in, gevolgd 
door 2 weken aspirine ’s avonds, of de omgekeerde volgorde. Aan het eind van 
beide perioden van 2 weken werd de bloedplaatjesactiviteit elke 3 uur gemeten. 
Het belangrijkste resultaat was dat aspirine-inname ’s avonds de bloedplaatjesac-
tiviteit tijdens de ochtenduren (6-12 uur) verlaagde met gemiddeld 23 Aru (95% 
bi: -50 tot 4). ook werd het serum tromboxane b2, een directe maat voor het effect 
van aspirine op bloedplaatjes, verlaagd tijdens de ochtenduren door aspirine ’s 
avonds in te nemen in plaats van ’s ochtends (gemiddeld verschil: -1.8 ng/ml [95% 
bi: -2.8 tot -0.8])
samengevat kunnen we uit de bevindingen in hoofdstuk 3 en hoofdstuk 4 con-
cluderen dat bloedplaatjesactiviteit tijdens de ochtenduren beter wordt geremd 
als aspirine ’s avonds wordt ingenomen in plaats van ’s ochtends.
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Advies aan patiënten die aspirine gebruiken
onze studie in hoofdstuk 3 suggereert dat bijwerkingen gemiddeld niet vaker 
voorkomen met aspirine-inname ’s avonds dan met inname ’s ochtends. Het lijkt 
dus veilig om aspirine ’s avonds in te nemen.
Aspirine-inname ’s avonds zorgde in dit onderzoek niet voor een verlaging van de 
bloeddruk. Wel was duidelijk dat de activiteit van bloedplaatjes in de ochtenduren 
beter geremd werd door aspirine ’s avonds in te nemen. dit zou voordelig kunnen 
zijn voor het voorkómen van hart- en vaatziekten in de ochtenduren, omdat de 
kans op het ontwikkelen van een bloedstolsel in een slagader (met een hart- of 
herseninfarct tot gevolg) groter is als de bloedplaatjesactiviteit hoger is. Aspirine 
remt de klonterneiging van bloedplaatjes, en een maximale werking van aspirine 
tijdens de ochtenduren zou een deel van het optreden van een bloedstolsel in 
de ochtenduren kunnen voorkomen. Wel moet worden opgemerkt dat in onze 
studies patiënten niet werden gevolgd om te onderzoeken of het optreden van 
hart- en vaatziekten in de ochtenduren inderdaad wordt verlaagd door aspirine ’s 
avonds in te nemen. dit zal toekomstig onderzoek moeten uitwijzen.
bAsAle bloedplAATJesAcTiviTeiT en risico op recidieF HArT- en 
vAATZieKTen
in hoofdstuk 5 werd onderzocht of hoge waarden van basale activiteit van bloed-
plaatjes, gemeten met ontstekingswaarden in bloed (nAp-2, cXcl4 en rAnTes), 
het risico op een recidief hartinfarct verhogen. de gedachte hierachter is dat deze 
bloedplaatjes-specifieke ontstekingswaarden bijdragen aan het ontstaan van 
aderverkalking (atherosclerose) en ontstekingscellen aantrekken in bloedstolsels. 
in totaal 542 mannen, die een hartinfarct hadden overleefd tussen 1990 en 1996, 
werden gemiddeld 9.2 jaar gevolgd. Tijdens de follow-up kregen 254 (47%) man-
nen een vorm van recidief hartinfarct. Het belangrijkste resultaat was dat hoge 
waarden van de gemeten ontstekingswaarden het risico op een recidief niet ver-
hoogden (gecorrigeerde hazard ratio’s: nAp-2: 1.1 [95% bi 0.8-1.7]; cXcl4: 1.2 [0.8-
1.8]; rAnTes 1.2 [0.8-1.8]). deze resultaten spreken eerder onderzoek tegen. een 
eerste mogelijke verklaring hiervoor is dat onze studiepopulatie stabiele patiënten 
vertegenwoordigde, terwijl eerdere studies juist patiënten met acute vormen van 
hart- en vaatziekte bestudeerden. Ten tweede is het mogelijk dat de verhoogde 
waarden in ons onderzoek niet bijdroegen aan het risico omdat bij onze patiënten 
(oudere mannen die een hartinfarct overleefden) andere klassieke risicofactoren 
veel meer aanwezig waren dan bij patiënten in een eerder onderzoek (jonge 
vrouwen). Als klassieke risicofactoren afwezig zijn, zoals bij jonge vrouwen, en zij 
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toch een hartinfarct krijgen, is het waarschijnlijk dat andere risicofactoren een veel 
grotere rol spelen.
uit deze studie kan geconcludeerd kan worden dat de basale activiteit van 
bloedplaatjes niet gerelateerd is aan het risico op recidief hart- en vaatziekten bij 
mannen die een eerste hartinfarct overleefden. dit sluit niet uit dat de basale ac-
tiviteit van bloedplaatjes, gemeten met ontstekingswaarden, van invloed kan zijn 
op het hart- en vaatziekten risico. Waarschijnlijk hangt dit af van de prevalentie 
van klassieke risicofactoren in de onderzochte populatie.
bèTA-bloKKers en bloedplAATJesreAcTiviTeiT
in navolging van internationale richtlijnen worden bèta-blokkers vaak voorgeschre-
ven aan patiënten met hart- en vaatziekten. bloedplaatjes spelen een grote rol bij 
het ontstaan van hart- en vaatziekten, maar het effect van bèta-blokkers op bloed-
plaatjesreactiviteit was nog onduidelijk. daartoe hebben werd in hoofdstuk 6 alle 
beschikbare literatuur hierover samengevat en het effect van bèta-blokkers op de 
bloedplaatjesreactiviteit samengevoegd in een meta-analyse. uiteindelijk werden 
31	studies	geïncludeerd	(28	experimentele-,	3	observationele	onderzoeken),	waarin	
in totaal 454 patiënten bestudeerd werden. Het belangrijkste resultaat was dat het 
gebruik van bèta-blokkers de bloedplaatjesreactiviteit verlaagde met gemiddeld 
13% (95% bi: 8-17%). verder vonden we dat dit effect het meest aanwezig was als 
adrenaline gebruikt werd om de bloedplaatjesreactiviteit te testen. ook verlaagden 
niet-selectieve lipofiele bèta-blokkers (zoals carvedilol) de bloedplaatjesreactiviteit 
meer dan selectieve niet-lipofiele bèta-blokkers (zoals metoprolol). samenvattend 
suggereert deze studie dat het beschermende effect van bèta-blokkers, naast een 
verlaging van het hartritme, bloeddruk en zuurstofbehoefte van het hart, mogelijk 
mede berust op een verlaging van de bloedplaatjesreactiviteit.
conclusies
de studies in dit proefschrift laten zien dat aspirine-inname ’s avonds in plaats van 
’s ochtends niet de bloeddruk, maar wel de ochtendpiek van bloedplaatjesactiviteit 
verlaagt van patiënten die aspirine gebruiken ter preventie van hart- en vaat-
ziekten. dit werd bevestigd in een 24-uurs ritme studie bij gezonde vrijwilligers. 
Toekomstig onderzoek moet uitwijzen of deze simpele interventie inderdaad leidt 
tot een verlaging van het risico op hart- en vaatziekten.
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uit onderzoek in dit proefschrift blijkt dat hoge waarden van basale bloed-
plaatjesreactiviteit, gemeten met bloedplaatjes-specifieke ontstekingswaarden, 
waarschijnlijk niet bijdragen aan het risico op een recidief hartinfarct in mannen 
die eerste hartinfarct overleefd hebben. in eerder onderzoek was verhoogde 
bloedplaatjesreactiviteit geassocieerd met het risico op hart- en vaatziekten. 
uit de meta-analyse in dit proefschrift blijkt dat bèta-blokkers, die vaak worden 
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Tobias nicolaas bonten werd op 1 augustus 1984 geboren in Heerlen. in 2002 be-
haalde hij zijn gymnasium diploma aan het bernardinus college te Heerlen, waarna 
hij 5 maanden rondreisde in Australië. in 2003 begon hij zijn studie Geneeskunde 
aan de universiteit leiden. Tijdens de doctoraal fase nam hij deel aan een uitwisse-
ling met het Karolinska instituut te stockholm. in het vierde jaar van zijn studie was 
hij als student assistent op de afdelingen verloskunde en neurologie van het leids 
universitair Medisch centrum (luMc) betrokken bij de praktische uitvoering van 
wetenschappelijk onderzoek. ook gaf hij op de snijzaal van het luMc anatomie 
les aan studenten geneeskunde. Aan het eind van zijn studie volgde een weten-
schappelijke stage op de afdeling infectieziekten van het luMc naar diagnostiek 
en predictie van gecompliceerde urineweginfecties. Tijdens deze stage volgde hij 
een cursus epidemiologie onder begeleiding van dr. J.d. snoep. Het arts-examen 
werd in april 2010 cum laude afgelegd, waarna hij werkte als arts-assistent interne 
geneeskunde in het diaconessenhuis leiden.
van december 2010 tot februari 2014 deed hij promotieonderzoek op de afdeling 
Klinische epidemiologie van het luMc onder begeleiding van prof. F.r. rosendaal, 
prof. J.G. van der bom en dr. J.d. snoep. Gedurende deze jaren bleef hij als arts-
assistent avond- en nachtdienst doen in het diaconessenhuis leiden en volgde hij 
de opleiding tot epidemioloog b onder begeleiding van prof. F.r. rosendaal en 
prof J.G. van der bom. de resultaten van het onderzoek naar het tijdsafhankelijke 
effect van aspirine op bloeddruk en bloedplaatjes activiteit zijn in dit proefschrift 
beschreven. ook werden de resultaten gepresenteerd op internationale congres-
sen, wat niet onopgemerkt bleef door nationale en internationale media. in 2013 
kreeg hij samen met prof. J.G. van der bom subsidie van het leids universitair 
Fonds om onderzoek te doen naar de invloed van het innametijdstip van aspirine 
op het 24-uurs ritme van bloedplaatjes activiteit.
sinds 1 maart 2014 volgt hij de opleiding tot huisarts in de regio leiden.
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